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Summary 
Adenosine is a small molecule suppressing the effector arm of the immune system and enhancing 
the activity of immunosuppressive cells. It is produced through the two-step hydrolysis of 
extracellular ATP by ectonucleotidases CD39 and CD73. These enzymes have been detected on 
various populations of immune cells as well as on tumor cells and they can contribute to the 
immunosuppression developed in the tumor microenvironment. The aim of the current study was 
to investigate the role of ectonucleotidases CD39 and CD73 in different subsets of immune cells 
in the regulation of anti-tumor immunity in tumor-bearing hosts. We used the ret transgenic 
mouse model of spontaneous melanoma and the orthotopic Panc02 model of pancreatic ductal 
adenocarcinoma that resemble the clinical situation. Patterns of ectonucleotidase expression on 
various immune cell subpopulations were analyzed with regard to their phenotype and function.  
We showed that CD39 and CD73 are strongly expressed on murine regulatory T cells (Tregs). 
Moreover, ectonucleotidase expression was detected on CD4 FoxP3
-
 conventional T cells 
(Tcons) and CD8 T cells. Notably, a significant fraction of tumor-infiltrating Tcons and CD8 T 
cells expressed CD39 or CD73 (especially in the Panc02 pancreatic adenocarcinoma model), 
thereby suggesting that the expression of ectonucleotidases on T cells might be influenced by the 
tumor microenvironment. Next, we found that Tcons with the activated phenotype (CD25
+
) were 
highly enriched in CD39
+
 and CD73
+
 cells. Furthermore, in vitro activated Tcons and CD8 T 
cells also contained increased frequencies of CD39
+
 cells, as compared to unstimulated cells. The 
observed upregulation of ectonucleotidases on T cells upon activation suggests a possible 
mechanism of negative feedback regulation through auto- and/or paracrine adenosine signaling. 
In memory CD4 T cells, the frequency of CD39
+
 and CD73
+
 cells was found to be significantly 
higher than within naïve CD4 T cells. Memory CD8 T cells displayed an enrichment in CD39
+
 
cells, whereas the numbers of CD73
+
 cells were similar in memory and naïve cell compartments. 
In addition, we found that IFN--producing CD4 and CD8 T cells harbored increased frequencies 
of both CD39
+
 and CD73
+
 cells as compared to respective IFN--negative populations. These 
data implied that CD39 and CD73 might mediate adenosine production by memory cells, thereby 
providing a mechanism of auto- and/or paracrine regulation to prevent an adverse memory T cell 
response.  
Studying the role of ectonucleotidases in CD11b
+
Gr1
+
 myeloid-derived suppressor cells 
(MDSCs), we demonstrated that the majority of CD11b
+
Ly6G
+
Ly6C
-
 granulocytic MDSCs 
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coexpressed CD39 and CD73. Importantly, the frequency of CD73
+
 cells in granulocytic MDSCs 
was significantly higher than in immature CD11b
+
Gr1
+
 myeloid cells considered as a counterpart 
of MDSCs in healthy mice. In addition, we observed a substantial frequency of CD73
+
 cells 
among monocytic MDSCs in pancreatic tumors. These data indicate that ectonucleotidase 
expression might contribute to the MDSC suppressive function in tumor-bearing hosts. Using the 
ret transgenic mouse model of melanoma, we showed that the administration of a CD73 inhibitor 
APCP or an A2a receptor antagonist SCH58261  prolonged the survival of tumor-bearing mice 
and reduced the MDSC infiltration into tumors, suggesting that this might be a promising strategy 
for cancer therapy. 
Taken together, we found that CD39 and CD73 might be involved in the regulation of T cell 
activation and memory as well as in the activity of MDSCs, suggesting that agents targeting 
adenosine production and signaling might be instrumental in the development of novel strategies 
for tumor immunotherapy. 
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Zusammenfassung 
Adenosin ist ein kleines Molekül, das die Effektorzellen des Immunsystems supprimiert und die 
Aktivität von immunsupprimierenden Zellen verbessert. Dies geschieht durch die zweistufige 
Hydrolyse von ATP durch extrazelluläre CD39 und CD73 Ektonukleotidasen. Diese Enzyme 
sind in verschiedenen Populationen von Immunzellen sowie auf Tumorzellen exprimiert und sie 
können zur Immunsuppression beitragen, welche sich in der Tumor-Mikroumgebung entwickelt. 
Das Ziel der vorliegenden Arbeit war, die Rolle von CD39 und CD73 Ektonukleotidasen in der 
Regulation der anti-Tumor-Immunität in tumortragenden Organismen zu untersuchen. Hierzu 
wurden unterschiedliche Populationen von Immunzellen betrachtet. Wir nutzten ret transgene 
Mäuse, welche spontan Melanome entwickeln, und das orthotopen Panc02 Mausmodell duktaler 
Adenokarzinome des Pankreas. Beide Modelle ähneln stark der klinischen Situation im Patienten. 
Die Expression von Ektonukleotidasen auf verschiedenen Subpopulationen von Immunzellen 
wurde hinsichtlich ihres Phänotyps und ihrer Funktion analysiert. 
Unsere Untersuchungen zeigten, dass CD39 und CD73 auf der Oberfläche von regulatorischen T-
Zellen (Tregs) in Mäusen stark exprimiert sind. Darüber hinaus wurde die Expression von den 
Ektonukleotidasen auf CD4
+
FoxP3
-
 konventionellen T-Zellen (Tcons) und CD8 T-Zellen 
beobachtet. Die tumorinfiltrierenden Tcons und CD8 T-Zellen enthalten große Anteile von 
CD39
+
 und CD73
+
-Zellen (insbesondere im Panc02 Pankreaskarzinommodell). Dies lässt 
vermuten, dass die Expression von den Ektonukleotidasen auf T-Zellen durch die Tumor-
Mikroumgebung beeinflusst werden könnte. Des Weiteren fanden wir, dass Tcons mit dem 
aktivierten Phänotyp (CD25
+
) in CD39
+
 und CD73
+
-Zellen stark angereichert wurden. Außerdem 
enthielten in vitro-aktivierte Tcons und CD8 T-Zellen  höhere Anteile von CD39
+
-Zellen als 
unstimulierten Zellen. Die beobachtete Hochregulation der Ektonukleotidasen auf den aktivierten 
T-Zellen könnte einen Mechanismus der negativen Feedback-Regulation durch auto- und/oder 
parakrine Adenosineffekte darstellen. Der Anteil von den CD39
+
CD73
+ 
Zellen in der Population 
der Gedächtnis-CD4-T-Zellen erwies sich als signifikant höher als in den naiven CD4 T-Zellen. 
Die Population der Gedächtnis CD8-T-Zellen zeigte eine starke Anreicherung an CD39
+
-Zellen, 
obwohl der Anteil der CD73
+
 Untergruppe ähnlich in naiven und Gedächtniszellen war. Darüber 
hinaus stellten wir fest, dass sowohl CD4 als auch CD8 IFN--produzierende T-Zellen einen 
höheren Anteil von CD39
+
 und CD73
+
-Zellen aufweisen im Vergleich zu den jeweiligen IFN--
negativen Zellpopulationen. Diese Daten deuteten an, dass CD39 und CD73 auf Gedächtniszellen 
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Adenosinproduktion vermitteln könnten. Damit stellen unsere Daten einen neunen Mechanismus 
der auto-und / oder parakrinen Regulation dar, der eine mögliche schädliche Gedächtnis-T-Zell-
Antwort verhindern könnte. 
Unsere Untersuchungen bezüglich der Rolle der Ektonukleotidasen auf CD11b
+
Gr1
+ 
Myeloiden 
Suppressorzellen (MDSCs) zeigten, dass die Mehrheit der CD11b
+
Ly6G
+
Ly6C
- 
granulocytischen 
MDSCs CD39 und CD73 koexprimieren. Wichtig ist, dass der Anteil an CD73
+
-Zellen unter 
granulocytischen MDSCs signifikant höher ist als unter unreifen CD11b
+
Gr1
+
myeloiden Zellen, 
welche in gesunden Mäusen als Gegenstück zu den MDSCs betrachtet werden. Darüber hinaus 
fanden wir einen wesentlichen Anteil an CD73
+
-Zellen unter monozytischen MDSCs in den 
pankreatischen Tumoren. Diese Daten deuten darauf hin, dass die Expression der 
Ektonukleotidasen auf den MDSCs zur Immunsuppression in einem tumortragenden Organismus 
beitragen könnten. Mit dem ret transgenen Mausmodell des Melanoms gelang es uns zu zeigen, 
dass die Verabreichung eines CD73-Inhibitors oder eines A2a-Rezeptor-Antagonisten 
(SCH58261) das Überleben von tumortragenden Mäusen verlängerte und gleichzeitig die 
Infiltration von MDSCs in den Tumoren reduzierte. Diese Substanzen könnten somit 
vielversprechend für eine Krebstherapie sein. 
Zusammenfassend ist festzuhalten, dass CD39 und CD73 sowohl in der Regulation der T-
Zellaktivierung und des T-Zellgedächtnisses als auch in der Aktivität von MDSCs beteiligt sein 
könnten. Dies deutet darauf hin, dass die Regulation der Adenosinherstellung und -signalkaskade 
in der Entwicklung neuer Strategien für Tumorimmuntherapien hilfreich werden könnte. 
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Abbreviations 
A 
A2AR   type-2A Adenosine receptors  
A2BR   type-2B Adenosine receptors  
ACT  adoptive cell transfer 
ADP  adenosine diphosphate 
AMP  adenosine monophosphate 
APC  allophycocyanin 
APC  antigen-presenting cell 
APCP  adenosine 5'-(, -methylene) diphosphate 
ARG1  arginase-1 
ATP  adenosine diphosphate 
ATRA  all-trans-retinoic acid 
 
B 
BM  bone marrow 
BSA  bovine serum albumine 
 
C 
cAMP  cyclic adenosine monophosphate 
CCL  C-C chemokine ligand 
CCR  C-C chemokine receptor 
CD  cluster of differentiation 
CNS1  conserved non-coding sequence 1 
CTLA-4 cytotoxic T lymphocyte antigen 4 
CTX cytoxan (cyclophosphamide) 
CXCL  C-X-C chemokine ligand 
CXCR C-X-C chemokine receptor  
Cy  cyanin 
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D 
DC  dendritic cell 
DKFZ Deutsches Krebsforschungszentrum 
DNA  desoxyribonucleic acid 
 
E 
EDTA ethylenediamine-tetra-acetic acid  
 
F 
FACS fluorescence activated cell sorting 
FBS  fetal bovine serum  
FCS  fetal calf serum 
FITC flourescein-isothiocyanat 
Foxp3  forkhead box P3 (transcription factor) 
FSC  forward scatter 
 
G 
GITR  glucocorticoid-induced tumor necrosis factor receptor-related protein 
G-CSF  granulocyte colony-stimulating factor 
GM-CSF granulocyte-macrophage colony-stimulating factor 
 
 
H 
HER2/neu Human Epidermal Growth Factor Receptor 2) also known as neu 
HLA  human leukocyte antigen 
HPV  human papilloma virus 
 
I 
IDO  indoleamine 2, 3-deoxigenase 
IL  interleukin 
IFN  interferon 
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IPEX  immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
ITIM  immunoreceptor tyrosine-based inhibitory motif 
 
K 
KLH   keyhole limpet hemocyanin  
 
 
L 
LAG-3  lymphocyte-activation gene 3 
LIN  lineage markers (CD3, CD14, CD19, CD20, CD56) 
LN  lymph nodes 
LPS   lypopolisaccharide 
 
M 
MART1 melanoma antigen recognized by T cells 1 
M-CSF Macrophage colony-stimulating factor 
MDA melanocyte differentiation antigen 
MDSC myeloid-derived suppressor cell  
MHC major histocompatibility complex  
 
 
N 
NDP nucleoside diphosphate 
NF-κB nuclear factor kappa B 
NK  natural killer cell 
NKT natural killer T cell 
NO nitric oxide 
iNOS inducible nitric oxide synthase 
 
P 
PBS phosphate buffered saline 
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PD-1  programmed death 1 
PDAC  pancreatic ductal adenocarcinoma  
PDE-5  phosphodiesterase-5 
PD-L1 programmed death ligand 1 
PE  phycoerythrin 
PerCP peridinin-chlorophyll-protein complex 
PMA  phorbol 12-myristate 13-acetate  
PMEL  premelanosome protein 
 
R 
RBC   red blood cell  
ret human ret proto-oncogene 
ret tg ret transgenic mice without macroscopically visible tumors 
ret tu ret transgenic tumor-bearing mice 
RNA ribonucleic acid 
siRNA small interfering ribonucleic acid 
ROS  reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
 
S 
SCF  stem cell factor 
STAT  signal transducer and activator of transcription (a family of transcription factors) 
SSC  side scatter 
 
T 
Tcon  conventional (FoxP3
-
) CD4 T cells 
TCR  T cell receptor 
Teff  effector T cells (Tcons and CD8 T cells) 
TGF-β  transforming growth factor beta 
Th  T-helper cell 
TIGIT  T cell immunoreceptor with Ig and ITIM domains protein 
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TIL tumor infiltrating lymphocyte 
TIM-3 T cell immunoglobulin and mucin domain-containing protein 3  
Tr1 type-1 regulatory T cells  
Treg  regulatory T cell 
iTreg  induced regulatory T cell 
nTreg naturally occurring regulatory T cell 
TRP tyrosinase related protein  
 
V 
VEGF   vascular endothelial growth factor 
VEGFR1 vascular endothelial growth factor receptor 1 
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1. Introduction  
The major role of the immune system in the host protection from malignancies has been 
progressively recognized over the last decades. Multiple studies in humans and animal models 
demonstrated a vigorous activation of innate and adaptive immunity in response to tumor growth 
(1). This is highlighted by the correlation between the tumor infiltration with leukocytes and the 
prognosis (1-4). However, although tumors often attract immune cells capable of recognizing and 
destroying tumor cells, establishment of chronic inflammation and immunosuppressive network 
hinders tumor eradication (5). The outcome of tumorigenesis is thus largely determined by the 
balance between anti-tumor immunity and numerous mechanisms of immune escape developed 
by the tumor (1). One of the main factors of tumor-associated immune suppression is the 
activation and recruitment of inhibitory immune cells, e.g. regulatory T cells (Tregs) and 
myeloid-derived suppressor cells (MDSCs). Over the last years, insights into the mechanisms of 
tumor-associated immune suppression led to the development of novel immunotherapeutic 
strategies that can significantly extend the survival of cancer patients (6).   
1.1 T cells in cancer 
Multiple genetic and epigenetic alterations in tumor cells provide a broad diversity of antigens 
that can be recognized by cells of the adaptive immune system (6). In the periphery, naïve T cells 
continuously sample antigens in the context of Major Histocompatibility Complex protein 
(MHC) until they encounter their cognate antigen, which, in the presence of costimulation, leads 
to their activation through T cell receptors (TCRs). In particular, tumor-specific T cells can 
become activated upon their stimulation with tumor-associated antigens presented by 
“professional” antigen-presenting cells (APCs), including dendritic cells (DCs), macrophages and 
B cells. However, antigen-experienced T cells are capable of directly recognizing antigens bound 
to MHC class I (MHC-I) on tumor cells (7).  
Tumor antigen-specific CD8 T cells (which are MHC-I-restricted) can, in principle, directly 
recognize different types of tumor cells, since MHC-I is ubiquitously expressed by virtually all 
nucleated cells. However, malignant cells often downregulate MHC-I expression (1, 7, 8).  
Professional APCs uptake, process and present tumor antigens to T cells in the context of MHC-
II or MHC-I (in the latter case, through a mechanism termed cross-priming) (7). In many cases, 
CD4 T cells are unable to recognize cancer cells directly due to the lack of MHC-II on most solid 
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cancers (9). Hematological malignancies represent an exception, since B and T cells can express 
MHC-II. However, in certain cases, solid cancers (e.g. over 40 % of melanomas) can also 
constitutively express MHC-II, (10).  
Upon migration to the tumor site, T cells can produce cytokines, chemokines and anti-angiogenic 
factors that affect tumor growth (1, 7). T cells may also exert direct cytotoxicity against tumor 
cells either through apoptosis-inducing molecules or through the release of cytotoxic granules (7). 
Mature CD8 T cells and certain subpopulations of CD4 T cells produce interferon-γ (IFNγ) and 
tumor necrosis factor (TNF)-, which can stimulate the immune response by upregulating the 
expression of MHC class I and II molecules on both tumor cells and APCs (1, 7). CD4 T cells 
can orchestrate many aspects of innate and adaptive immunity, including the function of 
cytotoxic CD8 T cells (1, 7). They can also engage and 'license' APCs, which in turn recruit 
additional T cells and promote the activation of the innate immune system (7, 9). 
Thus, one of the greatest challenges in the field of immunotherapy is the identification of tumor 
antigens that can be used to redirect the immune system against the tumor with minimal side 
effects in patients (11). 
1.1.1 Tumor-specific T cells and adoptive T cell therapy 
Tumor-specific T cells can recognize differentiation and germline antigens, products of mutated 
genes, as well as viral antigens (7). In melanoma patients, it has been shown that tumor-
infiltrating lymphocytes (TILs) can be isolated from tumors and expanded ex vivo in the presence 
of interleukin-2 (IL-2). Upon reinfusion, the expanded cells can traffic to the tumor and, in some 
cases, cause tumor regression (7, 12). Such therapy is called adoptive cell transfer (ACT). 
Usually, it is preceded by so-called „preparative lymphodepletion“(temporary ablation of 
lymphoid cells). The latter can be achieved either through chemotherapy alone or in combination 
with total-body irradiation. The combination of preparative lymphodepletion with ACT and 
administration of IL-2 can lead to tumor eradication in patients with metastatic melanoma (or 
other tumor entities, including leukemia and synovial cell sarcoma) who failed to benefit from 
other treatment modalities (7, 9, 12, 13). 
Transformed cells often over-express respective tissue-specific differentiation antigens (7). This 
offers an opportunity to use those antigens as targets for ACT or vaccination (14, 15). However, 
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such therapies might entail severe adverse effects, since the targeted antigens are expressed in 
healthy cells and tissues as well (15). For example, patients who have responded to 
immunotherapies targeting CD19 on B cell lymphomas also experience long-term depletion of 
normal polyclonal CD19
+
 B-lineage cells (16). 
Melanocyte differentiation antigens (MDAs) - such as PMEL (also known as gp100), melanoma 
antigen recognized by T cells 1 (MART-1), tyrosinase, tyrosinase-related protein 1 (TRP-1) and 
TRP-2 - are expressed in most melanoma lesions. Importantly, they are also present in normal 
melanocytes in the stratum basale of the skin, in the retinal pigmented epithelium and in the inner 
ear, where they are associated with melanin production (15). Early antigen-cloning studies 
suggested that self-MDAs could be promising targets for T cell-based therapy (17). However, T 
cells with gene-engineered TCRs specific for PMEL or MART-1 caused a destruction of normal 
melanocytes in the skin, eyes and ears of treated patients (18). Objective clinical responses were 
observed in 9 out of 36 (25%) patients treated in these trials, but only one patient showed a 
complete response to the treatment. In contrast, TILs usually cause no apparent toxicity, although 
they have TCRs specific for the same self-antigens (19). Recent data on the melanoma exome 
indicated the presence of a large number of mutational changes (20, 21), which allows targeting 
non-synonymous mutations that result in the creation of new epitopes. It has been shown that 
tumor-specific antigens harboring particular point mutations can be recognized by tumor-
infiltrating effector T cells from melanoma patients (22). 
Certain tumors caused by transforming viruses can express viral products, which represent 
attractive targets, since they are absent from normal tissues. In particular, it is possible to target 
oncogenic proteins encoded by cancer-associated viruses such as those derived from Epstein–
Barr virus and human papillomavirus (HPV) (7).  
In some tumor entities, epigenetic alterations can trigger expression of non-mutated proteins 
termed cancer germline antigens or cancer-testis antigens (8, 23). These antigens are normally 
expressed in germline cells in the testes and fetal ovaries. Genes encoding cancer-testis antigens 
are silent in normal non-germline tissues but can be activated in many types of tumors (23). 
Importantly, T cells do not recognize these antigens on male germline cells because these cells 
lack MHC molecules (24). Tumors commonly expressing cancer testis antigens include 
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melanomas, lung carcinomas as well as head and neck, oesophagus and bladder cancers (25). 
Therefore, cancer testis antigens are among the most attractive targets for cancer immunotherapy. 
1.1.2 Role of T cell subsets in anti-tumor immunity 
Recent studies focusing on the clinical impact of TILs in solid tumors (the frequencies of CD3, 
CD4, CD8, FoxP3 and ratios between them) showed that the presence of CD3, CD8, as well as a 
high CD8/FoxP3 ratio are indicative of good prognosis (9, 26). In addition, the density and 
distribution of TILs were shown to independently predict the sentinel lymph node status and 
survival in patients with melanoma (27). Studies by Fridman  et al. (reviewed in (28)) showed 
that both CD8
+
CD45RO
+
 memory cells and IFN--producing T helper type 1 (Th1) cells 
represent positive prognostic factors in the vast majority of tumor entities. Moreover, Galon et al. 
(29) have shown that CD8
+
CD45RO
+
 T cells in the core of the tumor represent a superior 
prognostic factor compared to the conventional clinical staging in colorectal cancer. Strikingly, 
low frequencies of T cells in the tumor core indicated a very poor prognosis even in patients with 
localized disease, similar to that of patients with concomitant distant metastasis. This suggested a 
particular clinical importance of CD8 memory T cells at the tumor site (9). 
On the other hand, suppressor CD8 T cells detected at quite high frequencies in cancer patients 
display strong suppressive properties (30). The lack of surface markers allowing 
immunohistochemical detection of these cells in biopsies complicates the interpretation of 
clinical data on CD8 T cell infiltration in tumors (9). 
The data on CD4 T cells are more ambiguous, which could be due to the higher plasticity and 
diversity of CD4 T cell subpopulations, which can sometimes play opposing roles (9). Moreover, 
tumor-specific effector CD4 T cells can be converted into immunosuppressive CD25
+
FoxP3
+
 
Tregs (31). In addition, certain organs harbor large numbers of Tregs, which underscores the role 
of the originating tissue in the immune response against cancer (9). Recently, multiple studies 
showed that a high CD8/Treg ratio can serve as a positive prognostic factor in many malignancies 
(9). Thus, despite the fact that FoxP3 is not solely expressed by Tregs, these data suggest a 
predominant expression of FoxP3 in cells with a pro-tumor activity. 
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1.1.3 Phenotypes of tumor infiltrating lymphocytes and the manipulation of immune 
checkpoints 
Tumor-infiltrating T cells show a remarkable phenotipic diversity (32). It has been demonstrated 
that tumor-infiltrating CD8 T cells display a higher expression of exhaustion markers than CD8 T 
cells in the peripheral blood or surrounding normal tissue (9). In melanomas, tumor-infiltrating 
CD8 T cells express the Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte Antigen-4 
(CTLA-4) (often simultaneously) at high levels (7). These two molecules represent major 
immune checkpoints, and the activation of respective signaling pathways leads to a profound 
inhibition of T cell activation, proliferation and function (6). 
CTLA-4 competes primarily with CD28 (a T cell co-stimulatory receptor) for their common 
ligands CD80 (also known as B7.1) and CD86 (also known as B7.2) (6). Upon antigen 
recognition, CD28 engagement by CD80 and CD86 provides the essential second signal for naive 
T cell activation (6). Since CTLA-4 has a much higher overall affinity for both ligands, it has 
been proposed that its expression on the surface of T cells dampens the activation of T cells by 
outcompeting CD28 in binding CD80 and CD86, as well as by actively delivering inhibitory 
signals to the T cell (6). Normally, CTLA-4 expression is induced in T cells upon their initial 
exposure to antigen. The level of CTLA-4 upregulation is largely determined by the intensity of 
the initial TCR-mediated signaling (6). High-affinity ligands induce higher levels of CTLA-4, 
which restricts the amplitude of the initial response. Naive and memory T cells express high 
levels of cell surface CD28 (6). On the contrary, CTLA-4 remains sequestered in intracellular 
vesicles. Once the TCR is triggered by antigen encounter, CTLA-4 is transported to the cell 
surface, in amounts proportional to the strength of TCR (and CD28) stimulation (6). Therefore, 
CTLA-4 provides a negative feedback loop to regulate T cell activation after the TCR stimulation 
with ligands of varying concentrations and affinities.  
In contrast to CTLA-4, the major function of PD-1 is to restrain the activity of T cells in 
peripheral tissues during an inflammatory response to infection and to prevent autoimmunity (6). 
This turns into a major immunosuppressive pathway in cancer. Activated T cells upregulate PD-1 
and continue to express it in tissues (6). Chronic antigen exposure, which is common in chronic 
viral infections and cancer, often entails high expression of PD-1 (6). This causes a state of 
exhaustion or anergy among antigen-specific T cells (6). Similarly to CTLA-4, PD-1 can shift the 
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balance from T cell activation to tolerance at the early stages of T cell responses to antigens 
within secondary lymphoid tissues (6). 
Tumor-infiltrating CD4 T cells also show high expression of PD-1 and CTLA-4 (9). The PD-1
+
 
fraction of TILs displayed impaired effector functions (6). The immune regulatory checkpoints 
PD-1 and CTLA-4 play a major role in the exhausted phenotype of TILs, and the blockade of 
these molecules has been shown to increase not only T cell effector functions but also their 
infiltration into tumor lesions (6). PD-L1 expression has been correlated with a decreased CD8 
infiltration, but the correlation with the overall survival or disease progression remains 
controversial and may differ with regard to different malignancies (33, 34). However, there is 
clear association between the blocking of these immune-blockade pathways, increased T-cell 
functionality, increased tumor infiltration and the clinical effect of these novel immunotherapies 
(9). 
1.2 Regulatory T cells 
Under physiological conditions, regulatory CD4 T cells are characterized by the expression of the 
forkhead box P3 (Foxp3) transcription factor and interleukin-2 (IL-2) receptor α-chain (CD25) 
and serve to prevent adverse immune reactions against self, food and environmental antigens 
(35). Mice with a loss-of-function mutation in Foxp3 lack functional Tregs and die of multi-organ 
autoimmune and lymphoproliferative reactions early in life (35). In humans, hypomorphic 
mutations in FOXP3 causes similar pathology termed immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome (36). Numerous studies have linked 
the Treg accumulation in tumors and peripheral blood of cancer patients to poor prognosis, 
making Tregs an attractive target for cancer immunotherapy (28, 37). Studies in animal models 
showed that Treg depletion or inhibition of Treg suppressive mechanisms can restore anti-tumor 
immunity, eventually leading to a decreased tumor growth or even tumor regression (4, 38). 
However, many recent publications challenged this simplistic view of Tregs as a major pro-
tumorigenic cell population in the tumor microenvironment. First, a variety of other cells has 
been implicated in the negative regulation of anti-tumor immune responses (39, 40). Second, it 
has been established that in certain malignancies, Treg accumulation can diminish tumorigenic 
inflammation and serve as a positive prognostic factor (41-43). Third, Tregs exhibit a significant 
phenotypical and functional heterogeneity with different subsets showing a distinct suppressive 
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efficacy and exploiting distinct suppressive mechanisms (44). Finally, Treg phenotype and 
function strongly differ in various tumor entities, underlining the necessity to investigate the 
specific role of Tregs in particular malignancies (45).  
1.2.1. Treg development: naturally occurring and induced Tregs 
During thymic differentiation, T cell receptor (TCR) signals of intermediate strength (together 
with IL-2 signaling) enable a number of CD4 single-positive thymocytes to escape deletion (35). 
This population is enriched for cells instructed to differentiate into naturally occurring Foxp3
+
 
Treg cells (nTregs) (35). While the development of nTreg cells in the thymus is promoted by 
increased affinity interactions with self-peptide-MHC complexes, the conversion of conventional 
CD4
+
CD25
-
FoxP3
-
 T cells (Tcons) into iTregs occurs in the periphery as a result of high-affinity 
TCR signaling together with suboptimal costimulation in the presence of transforming growth 
factor (TGF)-β and IL-2 (35, 46). These cells can arise in the response to stimulation with foreign 
as well as tumor-associated self- or altered self-antigens under tolerogenic conditions (35, 46). 
The TCR repertoire of iTregs largely differs from that of nTregs (35). In particular, it has been 
suggested that iTreg often descend from Tcons recognizing antigens from the environment or 
commensal microbiota (47-50). This implies that iTregs play an important role in the post-thymic 
education of the immune system and adaptive tolerance (50). 
The TGF-β signaling is essential for the induction of Foxp3 in peripheral CD4 T cells (35). IL-2 
is required for the TGF-β-mediated induction of Foxp3 in peripheral T cells in vitro (35, 46, 51). 
IL-2 activates the Foxp3 locus through STAT5 and enhances the viability and proliferation rate 
of target cells in the presence of TGFβ (52). IL-2 also inhibits the development of T helper 17 
(Th17) cells (53). Moreover, IL-2 is indispensable for the homeostasis of fully differentiated Treg 
cells (54).  
Type 1 regulatory T cells (Tr1), characterized by IL-10 production, can be induced by the 
suboptimal activation and TGF- signaling (55, 56). However, the Tr1 differentiation requires 
high IL-10 levels and they might be Foxp3
- 
(55, 57). These data indicate that iTregs and Tr1 may 
represent competing and alternative cell lineages. It has been proposed that tumor antigen-
specific nTregs and iTregs contribute to the pool of tumor-infiltrating Tregs (58). Moreover, the 
Treg stimulation with tumor antigens may trigger vigorous proliferation of both nTregs and 
iTregs, significantly increasing their numbers in the tumor (59). Recently, Rudensky‟s group 
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generated mice with a deleted CNS1-element, an intronic Foxp3 enhancer, which is essential for 
the differentiation of iTreg but not nTreg cells (60). This model has already been applied to 
determine the role of iTregs in mucosal Th2 inflammation (61) and maternal-foetal conflict (62).  
1.2.2 Treg phenotype and identification 
In mice, Foxp3 appears to be a necessary and sufficient marker for the identification of bona fide 
Tregs (35), although it has been detected in a minor fraction of recently activated Tcons (63). 
However, in humans, FOXP3 is expressed in a significant proportion of activated Tcons (36), 
which requires the use of additional markers for an accurate analysis of human Tregs. Tregs are 
routinely defined and isolated based on the surface expression of CD25, although it can also be 
expressed on activated Tcon (55). Therefore, much attention has been focused on finding further 
markers that would allow a robust Treg detection and sorting. For instance, several studies 
suggested that IL-7-receptor, CD127 is expressed on conventional but not on regulatory T cells 
(64). However, CD127 is not an ideal biomarker for the identification of Tregs. First, some early 
activated Tcon also downregulate the CD127 expression (65). Second, activated Tregs can be 
CD127
+
 (66). Another study  showed that the integrin CD49d is present on most pro-
inflammatory CD25
high
 cells but virtually absent in the Treg compartment (67); it can be used in 
conjunction with CD127 to improve the purity of sorted Treg preparations. Indeed, sorting of 
CD25
high
CD127
low/-
CD49d
-
 Tregs, with subsequent analysis of FoxP3 expression is now 
becoming a standard method for human Treg isolation (68). 
1.2.3 Mechanisms of suppression 
Tregs inhibit the activity of various immune cell types, e.g. CD4 and CD8 T cells, B cells, DCs), 
natural killer (NK) and NKT cells both in vitro and in vivo (31, 35). In vitro, Tregs show 
hyporesponsiveness, i.e. low proliferation rate in the response to stimulation (36, 57). However, a 
significant proportion of Tregs exhibit a vigorous homeostatic proliferation in vivo, probably 
reflecting a high turnover rate or representing a consequence of recurrent interactions with 
cognate antigens (45). Tregs inhibit immune responses in an antigen-unspecific manner but their 
suppressive function is activated upon antigen-specific stimulation (69). 
Treg suppressive effects are mediated by a wide variety of mechanisms. These include surface 
expression of inhibitory or cell-death-inducing molecules, secretion of immunosuppressive 
cytokines, production of inhibitory molecules and direct cytolysis. Tregs express high levels of 
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CD25 (IL-2 receptor α-chain) and thus can compete with effector T cells (Teff) for IL-2 and 
hamper their proliferation (70). The inhibitory co-receptor CTLA-4 is constitutively expressed on 
Tregs at high levels and plays an important role in the Treg suppressive function (71). CTLA-4 
interaction with co-stimulatory molecules B7-1 and B7-2 on DC leads to the upregulation of the 
suppressive enzyme indoleamine 2, 3-dioxygenase (IDO) in antigen-presenting cells (APC), and 
the subsequent suppression of T cell activation and function (72). Moreover, IDO itself is a 
strong inducer of Treg differentiation (73).  
There are several other surface molecules that Tregs use to inhibit the APC activity. For instance, 
LAG-3, a CD4 homolog and a high-affinity ligand of MHC class II, contributes to the 
suppressive activity of both nTregs and iTregs (74). Ligation of MHC on DCs through LAG-3 
leads to the inhibition of their maturation and function (75). A recently discovered protein TIGIT 
is highly expressed on Tregs and activated Tcons, representing another example of Treg-
mediated control of the DC activity. During Treg-DC interactions, TIGIT induces IL-10 and 
TGF-β production by DC (76). Besides contact-dependent immune suppression, Tregs can also 
elaborate a variety of suppressive cytokines, most notably TGFβ and IL-10, which proved to be 
essential for the Treg homeostasis and function in vivo (77-79).  
Several mechanisms of the Treg-mediated immune suppression involve production of molecules 
disrupting metabolic pathways and signaling in target cells. For instance, Tregs can transfer the 
second messenger cyclic AMP (cAMP) into target cells through gap junctions, which dampens 
the proliferation and activity of target cells (80). Another mechanism leading to the cAMP 
elevation in effector cells is the Treg-mediated adenosine production through the enzymatic 
activity of cell-surface enzymes CD39 and CD73 (81). These proteins can convert pro-
inflammatory ATP into immunosuppressive adenosine in a two-step process: CD39 hydrolyses 
ATP or ADP into AMP, and CD73, in turn, cleaves AMP yielding adenosine (82). However, 
extracellular enzymes adenylate kinase and nucleoside diphosphate (NDP) kinase can 
phosphorylate AMP and ADP respectively, thus antagonizing CD39 activity (83). In contrast, 
adenosine can only be phosphorylated inside the cell by adenosine kinase, although it can also be 
inactivated in the extracellular space by adenosine deaminase. Remarkably, despite the necessity 
of CD73 for adenosine synthesis under physiological conditions, CD73-deficiency is usually 
complemented by compensatory overproduction of alkaline phosphatases (83). 
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Adenosine activates four distinct G-protein-coupled receptors: A1, A2A, A2B, and A3 (82). The 
A1 and A3 adenosine receptors are coupled to the Gi/o subunit, and their activation leads to the 
inhibition of adenylate cyclase, cAMP production, and protein kinase A activation. An 
engagement of these receptors also activates the phosphatidylinositol 3-kinase pathway (82). 
Activation of A2A and A2B largely accounts for immunosuppressive effects of adenosine. These 
receptors are coupled to the Gs subunit that activates adenylate cyclase, thus leading to enhanced 
cAMP synthesis and subsequent inhibitory effects on target cells (81). However, in contrast to 
other adenosine receptors, A2B is a low-affinity receptor and can only be activated at high levels 
of adenosine generated in response to pathological conditions (82). 
A2a receptors (A2AR) are expressed on a variety of immune cells (monocytes/macrophages, 
granulocytes, lymphocytes, DCs and NK cells) (82, 84). The A2AR-triggered cAMP elevation 
inhibits effector functions of all these cell populations. In particular, adenosine impedes the 
phagocytic capacity of macrophages, degranulation of neutrophils and IFN-γ production by NK-
cells (82). It also drives DC differentiation towards a population producing immune suppressive 
factors, such as TGF-β, prostaglandin E2, IDO etc. (85). An adenosine-mediated cAMP 
accumulation and inhibition of the NF-κB pathway (86) in T cells hinders their activation, 
proliferation, survival and effector functions (87, 88). 
Adenosine production strongly contributes to the Treg immunosuppressive activity (83, 89). 
Tregs from CD39-deficient mice are constantly activated but fail to suppress effector T cell 
proliferation (88). Furthermore, in CD73-deficient mice, activated CD4 T cells show an enhanced 
production of pro-inflammatory cytokines (IFN-γ, IL-2 and TNF-α), and Tregs completely lack 
their suppressive activity (90).  Therefore, it was hypothesized that CD73-derived adenosine 
ensures a tonic inhibition of NF-κB in CD4 T-cells, thereby restricting the development of 
effector T cell responses (90). CD39 and CD73 on Tregs play an important role in regulating the 
balance between the pro-inflammatory ATP and immunosuppressive adenosine. ATP can 
accumulate outside the cell both under normal and pathological conditions. In the context of 
inflammation and cancer, ATP is released by activated leukocytes, dying, injured or stressed cells 
(83).  
The effects of ATP-mediated signaling are concentration-dependent. High ATP concentrations 
activate NLRP3 inflammasome through P2X7 receptors, which leads to the activation of caspases 
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and cell death (91). Low ATP concentrations can trigger the influx of calcium into the cytoplasm 
or inhibit the synthesis of immunosuppressive cAMP through various P2Y receptors (92). Thus, 
the regulation of the ratio between extracellular ATP and adenosine by CD39 and CD73 on Tregs 
provides a means of tipping the balance between an immune activation and suppression. 
However, the role of CD73 in the human immune system appears to differ significantly from that 
in animal models. Importantly, while murine Tregs stably express CD73 on the cell surface, in 
human Tregs, CD73 can only be detected inside the cell (93). This challenges the notion that 
human Tregs can mediate the whole cascade of ATP conversion into adenosine, thereby 
suggesting that other cell populations might be involved in catalyzing AMP dephosphorylation.   
Another means of Treg-mediated immune suppression is direct cytotoxic activity against effector 
immune cells (57). Tregs can release cytolytic molecules such as granzyme A/B, perforin or 
activate the tumor necrosis factor related apoptosis inducing ligand-death receptor-5 pathway.  
Thus, Tregs deploy a wide variety of mechanisms to control the effector arm of immunity. This 
paves the way for the development of numerous strategies to alleviate Treg suppressor function 
in cancer patients aiming to improve the anti-tumor immune responses. 
1.2.4 Therapeutic targeting of Tregs 
Current strategies to target Tregs in cancer include Treg depletion as well as a blockade of the 
Treg immunosuppressive activity and migration.  Treg depletion has been widely used to restore 
the anti-tumor immunity and to improve the efficacy of vaccination and adoptive cellular 
immunotherapy in cancer patients and tumor-bearing mice (38). Depletion agents used in clinical 
and preclinical studies include low-dose chemotherapeutics, anti-CD25 antibody (daclizumab), 
IL-2-difteria toxin fusion protein (denileukin diftitox, ONTAK) and CD25-targeting 
immunotoxins (45, 94). However, current depletion strategies do not allow a specific Treg 
targeting since the latter share CD25 expression with activated Tcons, and their high proliferative 
activity makes them sensitive to chemotherapy (45). However, these approaches proved 
instrumental when Tregs significantly outnumber activated Tcons in the tumor 
microenvironment. Therefore, Treg depletion might restore the activation, migration, 
proliferation and activity of remaining Tcons (38). 
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1.2.4.1 Low-dose chemotherapy 
The high proliferation rate of Tregs makes them more sensitive to chemotherapy than effector T 
cells  (45). Therefore, certain chemotherapeutic regimens might lead to a selective Treg 
depletion. This was confirmed by studies, showing that anti-tumor effects of certain 
chemotherapeutic agents have distinct mechanisms, depending on the dose regimen (95). 
Metronomic (low-dose) cyclophosphamide (CTX) administration have been shown to improve an 
anti-tumor immunity and vaccination efficacy through Treg depletion, whereas high-dose 
regimens exerted direct cytolytic effects on tumor cells, causing an immunosuppression (95).  
The results of an early study by Polak and Turk (96) indicated that CTX might reverse the 
immune tolerance by targeting a yet unidentified suppressive T-cell population. Further 
investigations confirmed this hypothesis. Machiels et al. (97) showed that immune-modulating 
doses of CTX, doxorubicin, and paclitaxel can boost anti-tumor effects of HER-2/neu-expressing 
whole cell vaccines and reduce mammary tumor growth in neu transgenic mice. The tolerance to 
the neu transgene observed in these mice recapitulates irresponsiveness to tumor antigens in 
cancer patients.  The administration of CTX at 50-150 mg/kg one day before vaccination was 
superior to CTX or vaccination alone. The reversed order of treatment proved to be ineffective. 
Moreover, higher doses of CTX were rather detrimental for the vaccination efficacy. Metronomic 
CTX treatment resulted in an augmented Th1 HER-2/neu-specific T cell response, indicating the 
reversal of tolerance. 
In a rat model of colon carcinoma, Ghiringhelli et al. (98) demonstrated that CTX reduces Treg 
numbers, leading to a restoration of peripheral T cell proliferation and innate killing activities. A 
single administration of CTX at 25 to 30 mg/kg depleted CD4
+
CD25
+
 T cells while sparing other 
lymphocytes, delayed tumor growth, and led to a complete tumor regression when followed by 
immunotherapy that had no curative effect when administered alone. Later, it was shown that 
metronomic CTX could also selectively deplete CD4
+
CD25
+
FOXP3
+
 Tregs in advanced cancer 
patients. In a study reported by Ge et al. (99), daily oral administration of 50 mg 
cyclophosphamide in patients with treatment-refractory metastatic breast cancer initially caused a 
depletion of more than 40% of Treg in the peripheral blood. However, during the treatment, Treg 
numbers gradually recovered. Nevertheless, the transient Treg depletion allowed an expansion of 
tumor antigen-specific T cells that persisted during the whole period of treatment. Notably, 
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numbers of tumor-reactive T effectors but not Tregs correlated with the disease stabilization and 
increased overall survival. 
Preclinical studies showed that low-dose CTX also decreases the functional activity of Treg cells. 
Lutsiak et al. (100) compared Tregs from cyclophosphamide-treated and control mice 2 and 10 
days after the treatment. Tregs from CTX-treated animals had a significantly diminished 
suppressive capacity, which was restored by day 10 upon the treatment.  
In a recent phase II randomized trial (101), Treg numbers, phenotype and function were 
rigorously monitored in the lymph nodes and peripheral blood of stage II-III melanoma patients 
vaccinated with HLA-A*0201-modified tumor peptides in conjunction with the low-dose CTX 
and low-dose IL-2 administration. CTX slightly decreased the number of circulating Tregs in the 
vaccinated patients followed by a complete recovery of Treg numbers despite the administration 
of additional CTX doses. However, the treatment resulted in a substantial reduction in Treg 
numbers as well as IL-10 and TGFβ production in regional lymph nodes. Interestingly, the 
frequency of activated Tregs was lower in the LNs of patients treated with CTX compared with 
that in the LN of control patients. This observation is in agreement with the preclinical data 
indicating that CTX selectively depletes cycling and effector/memory Tregs with enhanced 
tumor-homing activity (102, 103).  
1.2.4.2 Treg depletion by CD25-targeting agents 
Several groups showed that prophylactic Treg depletion with anti-CD25 mAb in mice triggered 
the rejection of syngeneic tumors (104, 105), although such treatment after the tumor inoculation 
was less effective. However, tumor rejection was substantially facilitated when the anti-CD25 
mAb administration was combined with the DC vaccination (106, 107), CTLA-4 blockade (108) 
or GITR stimulation (57, 109). Since CD25 is expressed not only on Tregs but also on activated 
CD4 and CD8 T cells, anti-CD25 therapy may entail concomitant deletion of effector T cells. 
Accordingly, in B16 melanoma model, it was observed that although CD25
+
 T cell depletion 
before vaccination enhanced the treatment efficacy, the administration of anti-CD25 mAbs before 
a rechallenge in pre-vaccinated mice significantly diminished the protective effect of vaccination 
(106, 108).  
In a clinical study, Jacobs et al. (110) evaluated the impact of anti-CD25 mAb treatment on the 
vaccination efficacy. Thirty HLA-A2.1
+
 metastatic melanoma patients were vaccinated with 
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mature DC loaded with the tumor peptide and keyhole limpet hemocyanin (KLH). Half of the 
patients were pretreated with daclizumab, a humanized blocking antibody against CD25. 
Daclizumab efficiently depleted all circulating CD25
high
 leukocytes (including 
CD4
+
FoxP3
+
CD25
high
 cells) within four days after daclizumab injection. The presence of 
daclizumab during DC vaccinations prevented the induction of specific antibodies but not the 
presence of antigen-specific T cells. However, these CD25
+
 T cells did not acquire effector 
functions. Daclizumab pretreatment had no significant effect on the progression-free survival as 
compared to that in the control group. A more recent study by Rech et al. (111) showed that 
daclizumab did not act through antibody-dependent or complement-mediated cytotoxicity but 
rather repressed FoxP3 expression selectively in CD25
high
CD45RA
-
 Tregs. Morevover, 
daclizumab-treated CD45RA
-
 Tregs lost suppressive function and acquired the ability to produce 
interferon-γ, indicating their reprogramming towards Th1 lineage. In a clinical trial monitored by 
the same group (111), daclizumab was administered in combination with an experimental cancer 
vaccine in patients with metastatic breast cancer. The treatment led to a substantial and prolonged 
decrease in Tregs. An effective CD8 and CD4 T cell priming and responsiveness to all vaccine 
antigens were observed in the absence of autoimmune reactions.  
Another CD25-targeting agent, denileukin diftitox (ONTAK) was initially approved as an anti-
neoplastic agent for the treatment of cutaneous T cell lymphoma (94). Denileukin diftitox 
consists of a fragment of diphtheria toxin fused to IL-2. Upon internalization, diphtheria toxin 
irreversibly inhibits protein synthesis, ultimately triggering cell death. In patients with renal cell 
carcinoma, ONTAK significantly reduced circulating Treg numbers and promoted the expansion 
of CD4 and CD8 T cells producing IFN-γ after the DC vaccination (112). However, clinical 
studies of ONTAK in patients with melanoma showed a variable efficacy in the Treg depletion 
and contradictory data on the clinical outcome. For instance, the ONTAK administration altered 
neither FoxP3 mRNA levels in CD4 T cells nor the suppressive activity of CD4
+
CD25
+
 T cells 
(113). None of the patients showed an objective clinical response. In contrast, Telang et al. (114) 
showed that ONTAK caused a transient depletion of Tregs, thereby promoting melanoma 
antigen-specific CD8 T cells. Moreover, in a phase II clinical trial, ONTAK treatment resulted in 
a partial response in 16.7% of totally 60 patients and markedly increased the one-year survival in 
the cohort of partial responders as compared to patients with the progressive disease (114). 
 
 
29 
 
Two clinical trials explored the administration of immunotoxins linked to CD25 antibodies: 
RFT5-SMPT-dgIgA, CD25-specific murine antibody linked to a deglycosylated ricin A chain 
(dgA) (115), and LMB-2, a fusion of a single-chain Fγ fragment of the CD25-specific, anti-Tac 
monoclonal antibody to a truncated form of the bacterial pseudomonas exotoxin A (116). The 
administration of RFT5-SMPT-dgA to six patients with metastatic melanoma led to a transient 
but consistent reduction in the number of CD25
high 
CD4 T cells in vivo (115). However, the 
decrease in total FoxP3
+ 
CD4 T cell numbers was not so drastic since the CD25
low/-
FoxP3
+ 
subpopulation of CD4
 
T cells escaped selectively the depletion and persisted at stable numbers. 
No objective clinical responses were observed. In another study, eight patients with metastatic 
melanoma received LMB-2 followed by the MART-1 and gp100-specific peptide vaccination 
(116). The LMB-2 administration resulted in a preferential, transient reduction (up to 79.1%) in 
circulating CD25
+ 
CD4 T cell numbers. FoxP3
+ 
CD4 Treg cells that escaped LMB-2-mediated 
depletion were CD25
low/-
. However, despite the decrease in Treg numbers, LMB-2 therapy failed 
to improve the immune and clinical responses. 
Thus, above mentioned Treg-depleting strategies transiently reduce the Treg numbers and 
function in the peripheral blood of some cancer patients. However, Tregs come back and the 
blocking of their activity becomes again necessary. 
1.2.4.3 FoxP3 vaccination 
Since FoxP3 is a “master regulator” transcription factor of Treg development and function, the 
vaccination against FoxP3 might lead to efficient Treg depletion, representing an interesting 
approach to neutralize the tumor-associated immune suppression. In the B16 melanoma model, it 
was shown that the vaccination with FoxP3 mRNA leads to a local intratumoral but not systemic 
depletion of FoxP3
+
 cells (106). Nevertheless, the paucity of tumor Treg was associated with the 
improved anti-tumor reactivity of TRP-2-specific cytotoxic T lymphocytes after an additional 
vaccination with TRP-2-loaded DC. The mechanisms of this preferential depletion of tumor Treg 
remain obscure. 
1.2.4.4 CTLA-4  
Similar to many other markers, CTLA-4 expression is shared by regulatory and activated T cells 
(57). There have been some conflicting data on the specific role of CTLA-4 expression in either 
subset. Mice with Treg-specific CTLA-4 knockout succumb to lymphoproliferation and 
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autoimmune diseases similar to Foxp3 deficiency (117). Nude mice reconstituted with 
splenocytes with CTLA-4-deficient Tregs showed an enhanced survival and decreased tumor 
growth as compared to the recipients of control splenocytes (117). On the other hand, it has been 
demonstrated (118) that although antibody-mediated CTLA-4 blockade on T effector cells 
significantly improved the survival of mice with B16 melanoma, a specific blockade of CTLA-4 
expressed on Tregs alone had no antitumor effects. The maximal prolongation of survival was 
achieved by concomitant CTLA-4 blockade in both regulatory and effector T cells. In stage IV 
melanoma patients, the therapy with the anti-CTLA-4 antibody ipilimumab reduced Treg 
numbers and restored TCR-dependent proliferation of effector T cells (98). Importantly, a 
randomised trial in a large cohort of patients with previously treated metastatic melanoma (119) 
showed a significantly increased overall survival upon the ipilimumab treatment.  
1.2.4.5 GITR  
Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) is a co-stimulatory 
molecule constitutively expressed on Tregs (45). It is also expressed at lower levels on resting 
effector T cells and is upregulated upon the T cell activation (38). GITR stimulation by agonistic 
antibodies or GITR ligands leads to the suppression of Treg activity and augmented proliferation 
of effector T cells (45). Administration of anti-GITR mAbs elicited a concomitant immunity in 
B16 melanoma-bearing mice (105). Moreover, GITR activation triggered the tumor regression in 
mice with methylcholanthrene-induced fibrosarcoma (120). In contrast to most depletion 
strategies, anti-GITR mAb therapy showed higher efficacy in mice with established tumors than 
in prophylactic settings (120). In addition, combination of GITR activation with the tumor 
antigen stimulation promotes tumor antigen-specific effector T cells (121). Thus, GITR 
represents an attractive target for cancer immunotherapy.  
1.2.4.6 OX40 
OX40 (CD134) is a costimulatory receptor expressed on Treg and activated Teff (45). OX40 
ligation promotes the T cell proliferation, cytokine production and survival (122). Furthermore, it 
can also inhibit the Treg differentiation and suppressive activity (123, 124). Studies in preclinical 
models demonstrated that the OX40 activation provides a strong protection against immunogenic 
tumors, although poorly immunogenic tumors are more refractory to the therapy (125). 
Interestingly, a recent study showed that, in the context of chemotherapy-induced lymphopenia,  
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the OX40 activation induced a novel CD4 T cell population, expressing the transcription factor 
eomesodermin and producing Th1 and Th2 cytokines (126). This subpopulation promoted 
eradication of advanced B16 tumors in mice, supporting the use of immune modulation in 
redirecting the polarization of CD4 T cells. These promising results suggest the necessity of 
further research to gain a better understanding of the role of OX40 in antitumor immunity.  
1.2.4.7 Extracellular adenosine metabolism and signaling 
In mice, Tregs coexpress ectoenzymes CD39 and CD73 producing immunosuppressive adenosine 
(81). Over the last years, multiple studies implicated the adenosine production by Treg in their 
inhibitory activity, and showed that targeting adenosine synthesis in vivo was a promising 
strategy to diminish tumor-mediated immunosuppression (87, 88, 93, 127-130). 
It has been well documented that the deficiency or inhibition of adenosine production and 
signaling significantly reduces the tumor growth by improving the anti-tumor immunity (87, 127-
131). One of the seminal studies showed that A2AR-deficiency promoted the rejection of 
established immunogenic tumors, and that the administration of A2AR antagonists reduced the 
tumor growth and metastasis (87). The anti-tumor effects of A2AR targeting were CD8 T cell-
dependent. Furthermore, in a transplantable breast cancer model, Stagg et al. (128) demonstrated 
the efficacy of anti-CD73 mAb therapy in reducing tumorigenesis and metastasis. This study, 
together with several others (87, 130), showed an importance of CD73 expressed on tumor cells 
in hindering the anti-tumor immune reactivity.  
A more recent research has been focused on the role of the host CD73 in tumor-mediated 
immunosuppression and on the specific contribution of various cell lineages to adenosine 
production. Using four different transplantable tumor models, Stagg et al. (127) found that CD73-
deficiency enhanced anti-tumor immune responses and resistance to experimental metastasis. The 
anti-tumor effect of the CD73 deletion was dependent on CD8 T cells and associated with an 
expansion of antigen-specific IFN-γ-producing CD8 T cells in the peripheral blood and tumor 
microenvironment. Experiments with the bone marrow chimeras indicated that both 
hematopoietic and non-hematopoietic expression of CD73 non-redundantly contribute to the 
tumor immune escape. Furthermore, CD73 expression at least partially accounted for the tumor-
promoting effects of Tregs. The pro-metastatic effect of host-derived CD73 was dependent on 
CD73 expression on non-hematopoietic cells. Complementary data of Wang et al. (129) 
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suggested that the enzymatic activity of CD73 on non-hematopoietic cells hindered leukocyte 
migration into the tumor site, whereas CD73 on hematopoietic cells suppressed a systemic anti-
tumor T cell expansion and their effector functions. Both groups demonstrated the anti-tumor and 
anti-metastatic effects of the CD73 targeting with a selective inhibitor α,β-methylene adenosine 
diphosphate (APCP) or respective monoclonal antibodies. Moreover, Wang et al. (129) showed 
that anti-CD73 mAbs could completely restore the efficacy of adoptive T cell therapy in tumor-
bearing mice. The translational significance of these findings is underscored by the fact that 
various adenosine receptor antagonists are already used in clinical settings for other indications 
(45).  
Thus, targeting adenosine production and signaling represents a promising strategy to restore 
spontaneous T cell-mediated anti-tumor reactivity and to improve the efficacy of adoptive 
cellular immunotherapy in cancer patients. Further studies are necessary to elucidate the role of 
adenosine in the human immune cells and their interactions with tumor cells in the tumor 
microenvironment and in the periphery. 
1.3 Myeloid-derived suppressor cells 
1.3.1 Subsets, phenotypes and development 
MDSCs represent a heterogeneous population of highly suppressive immature myeloid cells 
(IMCs). In mice, MDSCs are identified by the co-expression of the myeloid-cell lineage 
differentiation antigen Gr-1 and CD11b (also known as αM-integrin) (132). MDSCs contain 
subpopulations of (Ly6G
+
Ly6C
low/-
) and monocytic (Ly6G
-
Ly6C
high
) lineages (132). In cancer 
patients, various sets of markers have been use to analyze or isolate MDSCs. In particular, Lin
–
HLA-DR
– 
CD33
+
CD11b
+
 MDSCs have been isolated from the peripheral blood of patients with 
glioblastoma, breast cancer, colon cancer, lung cancer or kidney cancer (40). These cells shared 
morphological and functional properties with granulocyte precursors. High frequencies of these 
cells correlated with a poor prognosis and radiographic progression in patients with breast or 
colorectal cancer (133, 134). Furthermore, the frequency of each MDSC subset appears to be 
influenced by the type of cancer. Polymorphonuclear MDSCs (CD11b
+
CD14
–
CD15
+
CD66b
+
VEGFR1
+
) were detected in patients with renal cancer, whereas 
CD14
+
CD11b
+
HLA-DR
low/– 
monocytic MDSCs were observed in the peripheral blood of patients 
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with melanoma, multiple myeloma, prostate cancer, hepatocellular carcinoma or head and neck 
cancer (40, 135-138).  
In the bone marrow of healthy mice, the CD11b
+
Gr-1
+
 population comprises 20–30% of all cells. 
However, CD11b
+
Gr-1
+
 cells make up only a small proportion (2–4%) of spleen cells and are 
absent from the lymph nodes (132). MDSCs accumulate in the bone marrow, spleen and 
peripheral blood, within primary and metastatic solid tumors, and to a lesser extent in lymph 
nodes. Tumors release multiple soluble factors, causing substantial alterations in the 
differentiation and function of myeloid cells. Cytokines such as GM‑CSF, G‑CSF, M‑CSF, stem 
cell factor (SCF), vascular endothelial growth factor (VEGF) and IL‑3 not only promote 
myelopoiesis but also block myeloid cell maturation (132, 139). Tumor-derived pro-
inflammatory factors (e.g. IL-1β, IL-6, S100A8 and S100A9), as well as cytokines released by 
activated T cells (such as IFNγ, IL-4, IL-10 and IL-13) convert IMCs into MDSCs (140). The 
tumor-derived factors CCL2, CCL12, CXC-chemokine ligand 5, prokineticin 2, S100A8 and 
S100A9 attract MDSCs to the tumor bed (40, 141). Interestingly, MDSCs can also be recruited 
by nitrated or nitrosylated CCL2, whereas effector CD8 T cells cannot, which may account for 
the selective accumulation of myelomonocytic cells within murine and human tumors (142).  
Lypopolisaccharide (LPS), in combination with IFN-γ, promotes MDSC expansion, probably 
through the inhibition of DC differentiation (143). Tumor-derived TGF-β also regulates MDSC 
accumulation and neutrophil polarization (144, 145). Tumors can also promote MDSC expansion 
through the release of small membrane vesicles – exosomes that contain signaling peptides, 
mRNAs, microRNAs and lipids (146). 
1.3.2 Mechanisms of immunosuppression 
In tumor-bearing mice, the granulocytic MDSC subset is the prevalent population of MDSCs. 
Polymorphonuclear MDSCs suppress antigen-specific CD8
 
T cells predominantly through 
production of reactive oxygen species (ROS) (40). Although granulocytic MDSCs represent the 
major subset of circulating MDSCs, they are less immunosuppressive than the monocytic 
counterparts when assessed on a per cell basis. Monocytic MDSCs express variable levels of 
usual monocytes markers, such as F4/80, CD115, Ly6C and CCR2 (40). This subset of MDSCs 
may also include progenitors that give rise to a subset of CD11b
hi
Gr-1
low
Ly6G–F4/80hiMHC-II+ 
macrophages with potent immunosuppressive properties. Monocytic MDSCs suppress CD8 T 
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cells predominantly via the expression of arginase-1 (ARG1) and inducible nitric oxide synthase 
(iNOS) and through the production of reactive nitrogen species. The increased activity of ARG1 
in MDSCs leads to the depletion of L-arginine from the microenvironment. The shortage of L-
arginine inhibits T-cell proliferation through several different mechanisms, including 
downregulation of TCR δ-chain expression and blockade of the cell cycle. NO and its derivatives 
cause T cell apoptosis, the nitration of chemokines and T cell receptors (TCR), blockade of T cell 
migration, cytokine production and cytotoxic activity.  
Another type of MDSC suppressive activity perturbs lymphocyte migration and viability (40). 
For instance, MDSCs express the membrane receptor ADAM17 (disintegrin and 
metalloproteinase domain-containing protein 17) that decreases CD62L levels on the surface of 
naive CD4 and CD8 T cells, thereby hindering T cell homing to secondary lymphoid organs 
(147). Furthermore, MDSCs express galectin-9, which binds to the T cell immunoglobulin and 
mucin domain-containing protein 3 (TIM-3) on lymphocytes and triggers T cell apoptosis (148). 
MDSCs also decrease the numbers and inhibit the function of mouse and human NK cells, mostly 
through membrane contact-dependent mechanisms, i.e. through membrane-bound TGF-β (in the 
case of mouse MDSCs) and through interaction with the NK cell receptor NKp30 (also known as 
NCR3) (40, 149).  
MDSCs have also been shown to activate and expand Tregs, which underscores the 
interdependence of these two major immunosuppressive populations (137, 150). MDSCs boost 
the clonal expansion of antigen-specific nTregs and induce the conversion of naive CD4 T cells 
into iTregs. Human CD14
+
HLA
-
DR
low/–
 MDSCs promote the transdifferentiation of Th17 cells 
into FOXP3
+
 iTregs through TGFβ and retinoic acid (40, 150). 
A recent study by Ryzhov et al. (151) suggests that the numbers and immunosuppressive activity 
of MDSC can be modulated by extracellular adenosine through A2BR. Furthermore, the authors 
detected high levels of CD73 on the surface of granulocytic MDSC and showed that the MDSC 
suppressive activity is enhanced in the presence of AMP, thereby suggesting that 
ectonucleotidase-mediated adenosine production might contribute to the MDSC function. 
1.3.3 Therapeutic targeting of MDSCs 
A large body of evidence indicates that the reduction of MDSC numbers and/or activity 
significantly improves anti-tumor immunity and improves the survival of tumor-bearing hosts 
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(39). Several strategies for targeting MDSC showed promising results in preclinical models (39, 
40). The first approach is to block MDSC generation from bone marrow progenitors and to 
promote the maturation of MDSCs into proficient APCs. The inhibition of the migration of 
MDSCs to the tumor and tumor-draining lymph nodes also showed therapeutic efficacy. Finally, 
it is important to inhibit the molecular pathways used by MDSCs to suppress T cell function.  
It has been shown that MDSC development can be blocked by targeting stem cell factor (SCF) 
(152, 153). Several studies showed that siRNA-mediated knockdown of SCF or inhibition of SCF 
signaling by anti-c-Kit antibodies or tyrosine kinase inhibitors (such as sunitinib, pazopanib and 
sorafenib) hinder MDSC development from bone marrow precursors in humans (in vitro) and 
mice (colon and Lewis lung carcinomas) (152, 153). A decrease in MDSC numbers was 
associated with improved tumor-specific immune responses, tumor regression and significantly 
prolonged survival. In addition, sunitinib has been demonstrated to reverse MDSC accumulation 
in patients with renal cell carcinoma, resulting in an expansion of Th1 cells and reduction in Treg 
numbers (154). In a mouse model of RCC, sunitinib was also found to neutralize the 
immunosuppressive functions of tumor-infiltrating MDSCs (154).  
Administration of all-trans-retinoic acid (ATRA) or ultra-low non-cytotoxic doses of paclitaxel 
has been shown to promote the differentiation of MDSCs into mature macrophages, DCs or 
granulocytes (155, 156). The combination of ATRA with G-CSF enhanced granulocyte 
differentiation, whereas ATRA together with vitamin D induced the development of monocytes 
(155). In a recent study, Sevko et al. (157) showed that the administration of the 
chemotherapeutic drug paclitaxel at ultra-low non-cytotoxic doses (previously described as 
chemoimmunomodulation (158)) in healthy C57BL/6 mice significantly reduced the frequency of 
CD11b
+
Gr1
+
 immature myeloid cells that are known as the MDSC counterparts in healthy mice 
(132). This was associated with an increase in NK cell frequencies in the bone marrow and their 
ability to produce IFN-γ. Moreover, paclitaxel-mediated chemoimmunomodulation enhanced the 
efficacy of vaccination with a peptide derived from melanoma-associated antigen tyrosinase 
related protein-2. Ultra-low dose paclitaxel administration in the ret transgenic (ret tg) mouse 
melanoma model led to a drastic reduction in MDSC frequencies as well as their ability to 
produce NO and to suppress T cell proliferation in vitro (159). Moreover, the concentrations of 
numerous chronic inflammatory factors (e.g. IL-1β, IL-6, TNF-α, IFN-γ, GM-CSF, and IL-10) in  
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melanoma lesions were significantly diminished. These changes were associated with a partial 
recovery of tumor-specific T cell responses that resulted in a delayed tumor growth and 
prolonged survival (159). 
Furthermore, MDSCs can also be sensitive to conventional chemotherapy (39, 40). A selective 
depletion of MDSCs has been achieved by the administration of gemcitabine (160) or 5‘-
fluorouracil (161). These agents depleted MDSCs with no apparent toxicity against other 
leukocyte subpopulations, which led to a markedly enhanced anti-tumor effect in several 
transplantable tumor models.  
Targeting of tumor-derived chemokines has also been applied to inhibit MDSC migration 
towards tumor lesions. Thus, prostate, breast and Lewis lung carcinomas, melanoma and 
colorectal cancer have been shown to produce various ligands for CCR2 (including CCL2) that 
attracted MDSCs and supported their suppressive activity (162, 163). For instance, direct CCL2 
binding by bindarit (164) or the blocking of production of these chemokine in tumors (162) has 
been shown to diminish MDSC frequencies in tumor microenvironment, to inhibit metastasis and 
neoangiogenesis and suppress the development of transplantable tumors.  
Finally, MDSCs could be neutralized through inhibition of their immunosuppressive activity. It 
has been reported that phosphodiesterase (PDE)-5 inhibitors (e.g. sildenafil or tadalafil) block 
MDSC immunosuppressive functions in various transplantable tumor models, which restores 
antitumor immunity and delays tumor growth (165-167). These effects were due to elevated 
intracellular concentrations of cyclic guanosine monophosphate leading to the down-regulation of 
iNOS and ARG-1 activities and decreased NO synthesis in MDSCs. 
In the ret transgenic mouse melanoma model, chronic administration of sildenafil caused a 
significant reduction in NO production and ARG-1 expression, which led to an improved anti-
tumor CD8 T cell response (168). Moreover, sildenafil significantly diminished chronic 
inflammation, which was manifested by a reduction in IL-1β, IL-6, VEGF, GM-CSF, CCL2, 
CCL3 and S100A9 production. All these changes resulted in a significantly prolonged survival of 
tumor-bearing mice. In addition to PDE-5 inhibitors, the activity of iNOS and ARG-1 can be 
directly blocked by corresponding inhibitors (165, 169) or by nitroaspirin (170), leading to a 
reactivation of T cells and strong anti-tumor effects.  
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Interestingly, some agents preventing the migration of MDSCs towards tumor lesions can also 
inhibit MDSC immunosuppressive function (39). In particular, COX-2 inhibitors that reduced 
MDSC trafficking mediated by chemokines CXCR4/CXCL12 and CXCR1-CXCR2/CXCL8, 
also impaired MDSC-mediated immunosuppression through the down-regulation of ROS and NO 
production or ARG-1 expression in these cells (171-173). 
1.4 Tumor models 
In the current study, we used two distinct tumor models – the ret tg mouse model of melanoma 
and the orthotopic Panc02 model of pancreatic ductal adenocarcinoma (PDAC).  
The ret tg model largely recapitulates human melanoma with respect to etiology, tumor genetics, 
histopathology and clinical development (174, 175). Tumor lesions show typical melanoma 
morphology and express melanoma-associated antigens, such as S100, tyrosinase, tyrosinase 
related protein (TRP)-1, TRP-2 and gp100. In these mice, the human ret transgene expression is 
controlled by the mouse metallothionein I promoter/enhancer, which allows its selective 
expression in melanin-producing cells (39, 174, 176). Ret belongs to the family of receptor 
tyrosine kinases and its activation promotes malignant transformation of melanocytes and tumor 
development in ret transgenic mice (177). Overexpression of the Ret kinase is associated with the 
activation of other kinases (such as mitogen-activated protein kinase and c-Jun) and matrix 
metalloproteinases acting downstream of the Ret kinase. After a short latency period (20–70 
days; mean, 40 days), transgenic animals develop skin tumors on the head (nose, ears, eyes), 
neck, back, or tail with metastases in lymph nodes, lungs, liver, brain, kidney, and bone marrow, 
similar to the metastatic pattern observed in melanoma patients. It was previously shown that skin 
tumors of these mice contain high frequencies of TRP-2-specific CD8 T cells, mostly exhibiting 
the effector memory phenotype (176, 178). Notably, these cells could be detected even at earlier 
stages of melanoma progression. Upon a co-incubation with DCs pulsed with melanoma lysates, 
bone marrow-derived T cells produced IFN- in vitro and exerted an anti-tumor activity after 
their adoptive transfer into melanoma-bearing ret tg mice. However, this anti-tumor effect was 
merely transient and failed to trigger tumor regression, probably subdued by the complex 
immunosuppressive network in the tumor microenvironment represented, for instance, by CD4 
Tregs and MDSCs (39, 92, 175, 176, 178). Indeed, a strong Treg accumulation in skin tumors 
and metastatic lymph nodes was observed at the early stage of melanoma  development (179).  In  
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addition, increasingly high frequencies of MDSCs were detected in skin melanomas and 
lymphoid organs during the course of tumor progression. Inhibition of MDSC 
immunosuppressive activity was shown to improve anti-tumor immunity and survival in tumor-
bearing ret tg mice (159, 168). 
Another model used in our work was an orthotopic model of pancreas adenocarcinoma (180, 
181). Panc02 tumor cells were injected directly into the pancreata of immunocompetent mice. 
The development of pancreatic tumors in their natural microenvironment constitutes an important 
advantage of that model. It has been found that Panc02 tumors are strongly infiltrated with Tregs 
(182). The vast majority of tumor-infiltrating Tregs, Tcons and CD8 T cells exhibited the 
effector/effector memory phenotype. In Tregs, this phenotype had been linked to an enhanced 
suppressive activity and proliferation capacity.  
Although a steady increase in TGF-β levels was observed in pancreatic tumors, treatment with a 
specific inhibitor of the TGF-β receptor I kinase failed to abrogate Treg accumulation (182). 
Targeting a major pathway of Treg migration with a CCR4 antagonist also did not affect Treg 
frequencies in the tumor. However, Panc02 tumors harbor high frequencies of cycling (Ki-67-
expressing) Tregs, which suggested that local proliferation might be the driving force of Treg 
accumulation in the tumor. Accordingly, Treg frequencies in the tumor were strongly reduced 
upon the administration of low-dose gemcitabine. This resulted in a modestly increased survival 
of tumor-bearing mice, thereby underscoring the contribution of Tregs to tumorigenesis in the 
Panc02 model. 
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2. Aims of the study 
Recent studies have shown that extracellular adenosine plays an important role in the regulation 
of various arms of the immune response. Several lines of evidence indicate that extracellular 
adenosine might be produced by a variety of cell types. In particular, it has been shown that 
adenosine can be elaborated by ectonucleotidases expressed on Tregs, MDSCs, endothelial cells, 
mesenchimal cells, cancer cells etc. However, recent studies suggested that ectonucleotidase-
mediated adenosine production might also be performed by certain types of effector T cells, in 
particular, IL-17-producing Th17 cells. Moreover, the patterns of ectonucleotidase expression in 
Tregs, Tcons and MDSCs, as regards to their subsets and anatomical location, remain largely 
unknown. Therefore, the goal of this work was to investigate the expression of CD39 and CD73 
on various subsets of T cells and MDSCs from tumors and lymphoid organs, in order to 
understand the role of extracellular adenosine in the regulation of immunity under homeostatic 
conditions and in cancer. In the current study, following issues were addressed: 
 - determination of the patterns of ectonucleotidase expression on Tregs in tumor-bearing mice 
and cancer patients; 
- elucidation of the role of CD39 and CD73 in the regulation of T cell activation and function. 
- investigation of the function of ectonucleotidases in the myeloid compartment, particularly in 
MDSCs. 
- evaluation of the therapeutic efficacy and immunological effects of CD73 inhibitors in vivo. 
 
 
 
 
 
 
 
40 
 
3. Materials and Methods 
3.1 Reagents 
3.1.1 Chemicals, buffers and media 
Product Company Catalogue number 
Bovine serum albumin (BSA) Sigma 7030-50G 
0,5M EDTA (pH 8.0) GIBCO  15575-098 
Fetal bovine serum (FBS) PAN Biotech, GmbH  3702-P260718    
Sodium azide (NaN3)      Roth K305 
0.4% Trypan blue solution Sigma T8154 
Phosphate buffer saline (PBS) PAA H15-002 
RPMI-1640, with L-glutamine PAA E15-840 
Red Blood Cell (RBC) Lysis Buffer  Biolegend 420301 
Penicillin-Streptomycin (P/S) PAA P11-010 
Phorbol 12-myristate 13-acetate (PMA) Sigma P1585 
Ionomycin calcium salt Sigma I3909 
Foxp3/Transcription Factor Staining Buffer Set eBioscience 00-5523-00 
Permeabilization Buffer (10X) eBioscience 00-8333-56 
Protein Transport Inhibitor (Brefeldin A) BD Biosciences 555029 
Adenosine 5′-(,-methylene)diphosphate Sigma M3763 
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3.1.2 Buffers and media 
Buffer / medium     Components 
FACS buffer:      1 x PBS   
2% FBS,  
0.2% NaN3  
2 mM EDTA 
Complete RPMI:     RPMI-1640 w/L-glutamine 
10% FCS      
1% P/S 
3.1.3 Antibodies 
Antibody Conjugate Isotype Company Catalogue No. 
anti-human CD3e V500 mouse IgG1,  BD 560770 
anti-mouse CD3e PerCP-Cy5.5 rat IgG2a,  BD 555276 
APC rat IgG2a,  BD 553066 
V500 syrian hamster IgG2,    BD 560771 
V450 syrian hamster IgG2,  BD 560352 
purified armenian Hamster IgG eBioscience 16-0031 
anti-human CD4 APC-H7 mouse IgG1,  BD 560158 
anti-mouse CD4 APC rat IgG2a,  BD 561091 
APC-Cy7 rat IgG2b,  BD 552051 
APC-H7 rat IgG2b,  BD 560181 
anti-human CD8 APC-H7 mouse IgG1,  BD 560179 
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anti-mouse CD8a APC-Cy7 rat IgG2a,  BD 557654 
APC-H7 rat IgG2a,  BD 560182 
anti-mouse CD11b PerCP-Cy5.5 rat IgG2b,  BD 550993 
FITC rat IgG2b,  BD 553310 
APC rat IgG2b,  BD 553312 
anti-human CD25 PE mouse IgG1,  BD 560355 
anti-mouse CD25 APC rat IgG2b,  BD 558643 
V450 rat IgG1,  BD 561257 
Anti-Mouse CD28 purified Golden Syrian Hamster 
IgG 
eBioscience 16-0281 
anti-human CD39 PE mouse IgG2b,  BD 555464 
anti-mouse CD39 PE-Cy7 rat IgG2b,  eBioscience 25-0391 
anti-mouse CD44 PE rat IgG2b,   BD 553134 
anti-mouse CD45 V500 rat IgG2b,  BD 561487 
anti-mouse CD45.2 PerCP-Cy5.5 rat IgG2a,  BD BD 552950 
anti-mouse CD45RB PE rat IgG2a,  BD 553101 
anti-mouse CD62L APC rat IgG2a,  BD 553152 
anti-human CD73 APC mouse IgG1,  BD 560847 
anti-mouse CD73 eFluor
®
 450 rat IgG1,  eBioscience 48-0731 
PE rat IgG1,  eBioscience 12-0731 
anti-human CD127 PerCP-Cy5.5 mouse IgG1,  BD 560551 
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anti-mouse Gr1 PE-Cy7 rat IgG2b,  BD 552985 
APC-Cy7 rat IgG2b,  BD 557661 
anti-human FOXP3 FITC rat IgG2a,  eBioscience 11-4776 
anti-mouse Foxp3 FITC rat IgG2a,  eBioscience 11-5773 
anti-mouse Ly6C APC rat IgG2b,  BD 553129 
3.2 Cell line 
Highly tumorigenic Panc02 cells were maintained in RPMI-1640 cell culture medium (PAA, 
Germany) supplemented with 10% FCS (PAA) at 37°C under 5% CO2. Cells were passaged by a 
brief detachment with 0.025% trypsin. The cells were routinely tested for contamination 
including mycoplasms. Cell cultivation was done by Mr. Markus Herbst (department of General 
Surgery, University Heidelberg). 
3.3 Routine laboratory materials and equipment 
3.3.1 Routine laboratory materials 
Material / instrument Type / model Company 
Needles 0,4x19 mm Mikrolance BD 
0,3x13 mm Mikrolance  BD 
Pipets  2-20 µl, 20-200 µl, 200-
1000µl  
Rainin 
Object carrier 76x26 mm SuperFrostPlus Menzel-Gläser 
Cover glass                    24 x 24 mm Roth 
Test tubes 5 ml / 15 ml / 50 ml  
0.5 ml / 1.5 ml / 2 ml  
BD Falcon 
Eppendorf 
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Syringes 1 ml   BD 
Cell culture plates 96-well flat bottom Platte  Greiner 
Cell strainer   40 µm; 100 µm  BD Falcon 
Sterile filter 0,45 µm, sterile  Roth 
3.3.2 Devices and equipment 
Equipment Model Company 
Flow cytometer FACS Canto II, 3 lasers BD 
Refrigerator (-80 °C) HeraFreeze Heraeus 
CO2 incubator HeraCell Heraeus 
Refrigerator (-20 °C)           Premium Liebherr 
Microscopes  DMIL Leica 
pH meter  766 Calimatic 
Laminar flow hood                                              Hera Safe Thermo Electron Cooperation 
Vortex  Vortex Genie 2 Scientific Industries 
Balance BP 3100P Sartorius 
Water bath DC3, HAAKE GFL 
Centrifuges Labofuge 400R Heraeus 
Biofuge primo R Heraeus 
Varifuge K Heraeus 
 
 
45 
 
 
3.4 Mice 
All mice were crossed and kept under specific pathogen-free conditions in the animal facility of 
the German Cancer Research Center (Heidelberg) or Heidelberg University. Experiments were 
performed in accordance with governmental and institutional guidelines and regulations.  
3.4.1 Ret transgenic spontaneous melanoma model 
Ret tg mice (C57BL/6 background) kindly provided by Dr. I. Nakashima (Japan) overexpress the 
human Ret proto-oncogene in melanocytes under the control of mouse metallothionein-I 
promoter-enhancer (177). Non-transgenic littermates and transgenic mice without 
macroscopically visible tumors were used as controls. The mice were kept and crossed under the 
guidelines of the animal facility of the German Cancer Research Center. 
3.4.2 Orthotopic model of pancreatic ductal adenocarcinoma 
Highly tumorigenic syngeneic murine Panc02 pancreatic ductal adenocarcinoma cells were 
injected into the head of the pancreas, producing rapidly growing tumors starting from day 5 after 
transplantation. Experiments were performed under the guidelines of the animal facility of 
Heidelberg University. Orthotopic transplantation was performed by Dr. Sabine Soltek or by 
Prof. Dr. Alexandr Bazhin (Department of General Surgery, University Heidelberg). C57BL/6 
mice were purchased from CharlesRiver (Germany).  
3.5 Software  
FlowJo (Version 7.6.1)   Tree Star, Inc., Ashland, USA 
GraphPad PRISM (Version 5) GraphPad Software, Inc., San Diego, USA 
3.6 Single cell suspensions  
3.6.1 Spleen 
Mouse spleens were collected into 2 ml Eppendorf tubes with 2 ml of ice-cold PBS (PAA). 
Single cell suspensions were prepared by mashing spleens with a plunger of a 5 ml syringe 
through a 40 µm cell strainer. Next, cell suspensions were centrifuged at 300g and the 
supernatant was discarded. Red blood cells were depleted by resuspending cell pellets in 1 ml of 
RBC lysis buffer followed by 3 min of incubation on ice. The reaction was stopped by adding 9 
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ml of PBS. Cells were subsequently centrifuged (300 g, 10 min), and the pellet was resuspended 
in FACS buffer at the concentration of 10
7 
cells/ml. 
3.6.2 Lymph nodes 
Isolated mouse lymph nodes were mashed on a petri dish using plunger of a 5 ml syringe and 
passed through a 40 µm cell strainer. Cells were washed with PBS (300 g, 5 min), and the pellet 
was resuspended in FACS buffer at 10
7 
cells/ml. 
3.6.3 Bone marrow 
Freshly isolated murine femurs and tibiae were cut at both ends and BM was flushed out with ice 
cold PBS using a 10 ml syringe with a 23G needle. BM was collected into a 10 cm Petri dish and 
subsequently transferred onto a 40 µm cell strainer. After the BM was mashed through the cell 
strainer, the resulting cell suspension was centrifuged, and red blood cells were depleted as 
described in 3.1.1. After washing with cold PBS (300 g, 5 min), the pellet was resuspended in 
FACS buffer at 10
7 
cells/ml. 
3.6.4 Tumor 
Freshly isolated tumor mass was mashed through a 40 µm cell strainer with a 5 ml syringe 
plunger. After the depletion of red blood cells, the cell pellet was resuspended in FACS buffer 
at10
7 
cells/ml. 
3.6.5 Cell numbers 
Cell numbers were determined using a Neubauer counting chamber. A sample of 10 µl was 
diluted with trypan blue at 1:100. The following formula was used: 
n x 10
4
 x dilution factor  = cell number / ml, where n= mean number of cells in a quadrant. 
3.7 Flow cytometry 
Single cell suspensions were dispensed into 5 ml polystyrene tubes at 10
6 
cells per tube and 
incubated for 15 min with the Fc-blocking reagent. Next, fluorescently labeled antibodies against 
surface antigens were added, followed by 15 min of incubation in the dark (at 4°C or on ice). 
Then, cells were washed twice with an excess of FACS buffer. When no intracellular staining 
was required, the cells were resuspended in 100 µl of FACS buffer and analyzed by flow 
cytometry with the FACS Canto II cytometer (BD) using the BD Diva Software V.6.1.1. At least  
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10,000 events were acquired for each population of interest. When necessary, intracellular 
staining for cytokines and transcription factors was performed. For this, cells were incubated in 1 
ml of Fixation/Permeabilization solution (eBioscience) for 30 min and subsequently washed 
twice with an excess of Permeabilization buffer (eBioscience). Next, cells were resuspended in 
50 µl of Permeabilization buffer and stained with fluorescently labeled antibodies against 
intracellular antigensAfter 30 min of incubation, cells were washed twice with the FACS buffer, 
resuspended in 100 µl of the same buffer and analyzed by flow cytometry. 
FlowJo software 7.6.1 (Tree Star) was used to analyze at least 10,000 events per population of 
interest. Data were expressed as pseudocolor dot plots.  
3.8 In vitro splenocyte activation 
Microwells of the assay plate were coated with anti-CD3 antibodies. To this end, a 10 μg/ml 
solution of anti-CD3 antibodies (eBioscience) in sterile PBS was prepared and 50 μL of the 
antibody solution were dispensed to each well of the assay plate. As a control, unstimulated cells, 
50 μl of sterile PBS were added. The plate was tightly covered with Parafilm™ to avoid sample 
evaporation and incubated at 37°C for 2 hours. Immediately before adding cells, the antibody 
solution was removed with a multichannel pipettor, and the wells were rinsed with 200 μl of 
sterile PBS three times.  
Single cell suspensions of splenocytes were centrifuged and resuspended in the complete RPMI-
1640 medium at 10
6
 cells/ml. Then 200 μL of the cell suspension were added to each well, and 
the plate was placed in a humidified 37°C, 5% CO2 incubator. Then soluble anti-CD28 
(eBioscience) antibody was added to the cells at 2 µg/ml. The kinetics of ectonucleotidase 
expression on splenocytes was analyzed by flow cytometry (as described in 3.2) at different time 
points (5, 24 and 48 hours) after the beginning of activation. 
3.9 Analysis of the IFN- production by T cells 
Single cell suspension of splenocytes was centrifuged, and the pellet was resuspended in 
complete RPMI at 10
6
 cells/ml. Next, 100 µl of the resulting cell suspension were dispensed to 
each well of a 96-well flat bottom plate followed by the addition of 100 µl of master mix 
containing 10 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma), 1 mM ionomycin (Sigma), 
and GolgiStop (BD Biosciences) (1.2 µl/ml). To the control wells, only GolgiStop was added.  
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After 5 hours of incubation, cells were stained with antibodies against surface markers, followed 
by the fixation/permeabilization and intracellular staining for IFN- according to the protocol 
described in 3.2. 
3.10 Survival analyses  
Ret transgenic tumor-bearing mice were injected intraperitoneally (i.p.) with APCP at 20 mg/kg 
or with SCH58261 at 5 mg/kg three times a week for 60 days. Mice were monitored daily for the 
tumor progression. The control group of mice with tumors of similar size received PBS. Each 
group comprised 15 animals. Two independent survival experiments have been performed.   
3.11 Statistical analyses  
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc.). The 
paired t-test using was applied to analyze the statistical significance where appropriate. Survival 
of tumor bearing mice was analyzed with Kaplan-Meier curves with subsequent Log-rank test. A 
p-value < 0.05 was considered significant. Values were expressed as mean ± SEM.  
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4. Results 
4.1. Expression of ectonucleotidases CD39 and CD73 on Tregs 
It was previously shown that the vast majority of murine Tregs express on their surface a high 
level CD39 and CD73, and adenosine production strongly contributes to Treg 
immunosuppressive properties (82, 83). However, patterns of the ectonucleotidase expression on 
Tregs from tumors and lymphoid organs remain poorly understood and deserve further 
investigation. To this end, we analyzed Tregs from tumors, bone marrow, spleens and lymph 
nodes of healthy mice and animals bearing melanoma or pancreatic adenocarcinoma (Fig. 1).     
Consistently with previously published findings, we found that Treg populations in the spleen 
contained 90-95% CD39
+
CD73
+
 cells (Fig. 2A), whereas only a minor proportion of CD4 Tcon 
and CD8 T cells coexpressed  CD39 and CD73. Moreover, the levels of CD73 on Tregs in 
spleens of healthy mice were far above those on Tcons and CD8 T cells, although CD39 
expression was comparable (Fig.  2B, C). These observations confirmed that Tregs possess the 
whole machinery of adenosine synthesis and can perform it more efficiently than other major T 
cell subsets.  
Remarkably, the patterns of ectonucleotidase expression on tumor-infiltrating T cells were 
distinctly different from what was observed in splenic T cells (Fig. 2D). In particular, only 60% 
of Tregs from melanoma lesions in ret transgenic mice expressed both CD39 and CD73. On the 
other hand, in both tumor models, we observed increased frequencies of CD39
+
CD73
+
 subsets 
among tumor-infiltrating Tcons and CD8 T cells as compared to these subsets in the spleen. This 
was especially pronounced in the Panc02 model, where approximately 50% of Tcons and more 
than 60% of CD8 T cells expressed both enzymes. Moreover, Tcons and Tregs from pancreatic 
tumors showed nearly the same expression level of both ectonucleotidases (Fig. 2E, F). These 
profound alterations might be due to the influence of the tumor microenvironment and/or to 
certain phenotypical and functional differences between T cell populations in the spleen and 
tumor. 
Next, we analyzed the expression of CD39 and CD73 on regulatory (FOXP3
+
CD25
high
CD127
low/
) 
and conventional (FOXP3
-
CD25
low/-
CD127
high
) T cells from the peripheral blood of patients with 
melanoma or  pancreatic  adenocarcinoma  and  healthy  donors  (Fig. 3A).   In contrast to mouse  
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Tregs, human regulatory T cells contained only a small population of CD39
+
CD73
+
 cells, which 
suggested that human Tregs have a very limited capacity to produce adenosine through enzymatic 
hydrolysis of extracellular nucleotides (Fig. 3B, C). However, we observed that approximately a 
half of the Treg subset showed CD39 expression, which indicates the ability of these cells to 
hydrolyze ATP. Only a small proportion of Tregs was positive for CD73 expression. Thus, 
human Tregs can contribute only to the first step of adenosine production outside the cell. 
Moreover, we detected a two-fold increase in the percentage of CD73
+
 cells in Tcons from 
melanoma patients, suggesting, in turn, an increased capacity to produce adenosine from AMP 
(Fig. 3D).Furthermore, we found that the CD73
+
 subset comprised only around 10%
 
of human 
Tcons, and the CD39
+
 population is also relatively small (Fig. 3D, E). Similarly to our findings in 
mouse models, we observed increased frequencies of CD39
+
 and/or CD73
+
 cells in human Tcon 
and Treg from the peripheral blood of cancer patients as compared to healthy donors. In 
particular, Tregs and Tcons from pancreatic cancer patients contained increased frequencies of 
CD39
+
 cells, indicating their enhanced capacity to hydrolyze ATP (Fig. 3E).  
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 Figure 1. Representative dot plots of murine pancreatic tumors (A) and spleens from tumor-bearing mice 
(B) showing gating strategy for the analysis of CD73 and CD39 expression on regulatory and 
conventional CD4 T cells (measured by flow cytometry).  
B 
A 
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Figure 2. Analysis of CD39 and CD73 expression on Tregs, CD4 Tcons and CD8 T cells in spleens (A-C)  
and tumors (D-F) of ret tg melanoma-bearing  mice (ret tu) and animals with pancreatic adenocarcinoma 
(Panc02) as well as healthy wild type C57BL/6 (wt) mice (measured by flow cytometry;  n=20;  
*p<0.001). 
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Figure 3. Representative dot plots of human peripheral blood showing gating strategy (A) for the 
analysis of ectonucleotidase expression on Tregs (B, C) and Tcons (D, E) in patients with melanoma or 
pancreatic cancer and healthy donors (measured by flow cytometry; *p<0.05; **p<0.01). 
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4.2. Analysis of ectonucleotidase expression on CD4 Tcons and CD8 T cells 
Since we found a relatively high expression of both ectonucleotidases also in non-regulatory T 
cells in melanoma and pancreatic cancer, we reasoned that it might be due to the alterations in the 
milieu and/or activation status of T cells. To address this suggestion, we compared the expression 
of CD39
 
and CD73 in CD25
-
FoxP3
-
 and CD25
+
FoxP3
-
 T cells (Fig. 4A-H). The latter subset 
presumably consists of activated T cells, since CD25 (IL-2 receptor α-chain) is induced on T cells 
upon activation (35). Importantly, CD25
+
FoxP3
-
 T cells from lymphoid organs and tumors 
contained significantly higher frequencies of CD73
+
 cells than their CD25
-
 counterparts. 
Accordingly, the CD25
+
 T cell subpopulation was highly enriched in CD39
+
 cells. This indicated 
that T cells may upregulate ectonucleotidases upon activation, which can possibly provide a 
negative feedback mechanism of autocrine regulation.  
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Figure 4. Analysis of CD39 and CD73 expression on Tregs, CD4 Tcons and CD8 T cells in spleens (A, 
B)  lymph nodes  (C, D), bone marrow (E, F) and tumors (G, H) of ret tg melanoma-bearing (ret tu) mice 
and animals with pancreatic adenocarcinoma (Panc02) as well as healthy wild type C57BL/6 (wt) 
(measured by flow cytometry; n=20; *p<0.05; **p<0.01; ***p<0.001). 
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To test this hypothesis, we activated normal murine splenocytes in vitro and analyzed the 
dynamics of CD39 and CD73 expression (Fig. 5A, B). Similarly to our ex vivo data, we observed 
a substantially higher percentage of CD39
+
 cells among activated CD4 T cells, compared to the 
non-activated control. However, we did not detect any significant changes in CD73 expression, 
which may reflect the differences in conditions of in vitro and in vivo T cell activation.  
Studying memory T cells, we found that both central (CD44
high
CD62L
+
) and effector memory 
(CD44
high
CD62L
-
) CD4
+
FoxP3
-
 subsets are highly enriched in CD39
+
 cells (Fig. 6A) as 
compared to naïve (CD44
low
CD62L
+
) CD4 T cells, which contained only a very low percentage 
of CD39-expressing cells. Similarly, the memory compartments of conventional CD4 T cells 
showed significantly higher frequencies of CD73
+
 cells than the naïve subset (Fig. 6B).   
Memory CD4 T cells are known to produce rapidly effector cytokines upon restimulation (183). 
Therefore, to determine if the association of ectonucleotidase expression with the memory 
phenotype has any functional implication, we analyzed CD39 and CD73 expression in the 
context of IFN-γ production by CD4 T cells from healthy wild type mice 5h after stimulation. 
Indeed, IFN-γ-producing cells contained a significantly higher percentage of CD39+ and CD73+ 
cells than IFN-γ-negative cells (Fig. 7A, B).  
Next, we asked if CD8 T cells also might exploit ectonucleotidases as a means of self-regulation. 
First, we found that virtually all CD8 T cells from lymphoid organs and tumors constitutively 
express CD73, suggesting that they might produce extracellular adenosine when AMP is 
available in their environment (Fig. 8A-D). However, CD39 expression appeared to be highly 
heterogeneous and varying between different lymphoid organs and the tumor site. In the spleen 
and lymph nodes, only a minor fraction of CD8 T cells expressed CD39 (Fig. 9B, C). In contrast, 
the CD39
+
 subset comprised 30-50% of CD8 T cells in the bone marrow (Fig. 9D). Remarkably, 
CD39
+
 cells represented the larger part of the CD8 T cell population in Panc02 tumors (Fig. 9A).  
In line with our data on activated CD4 Tcons, in vitro activation of CD8 T cells led to a two-fold 
increase in the percentage of cells expressing CD39
 
(Fig. 10). This suggested that activated CD8 
T cells upregulate CD39 in order to hydrolyze the excess of ATP released upon activation. 
Furthermore, similar to Tcons, memory CD8 T cells were enriched in CD39
+
 cells (Fig. 11). In 
particular, effector memory CD8 T cells contained the highest percentage of CD39
+
 cells, and in 
the central memory compartment, the frequency of CD39-expressing cells was higher than in 
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naïve cells (Fig. 11A). Furthermore, the proportions of CD39
+
 and CD73
+
 subsets were 
significantly increased within IFN--producing CD8 T cells. (Fig. 12A, B).  
Taken together, these data suggest that CD39 and CD73 ectonucleotidase may play an important 
role in CD4 and CD8 T cell activation and memory. In particular, in recently activated T cells, 
they may mediate a negative feedback mechanism restricting excessive activation, proliferation 
and effector function. In memory T cells, these enzymes may serve to prevent adverse activation 
of recall response. 
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Figure 5. Analysis of the expression of CD39 (A) and CD73 (B) on CD4 Tcons from spleens of healthy 
mice after the activation of T cells with antibodies against CD3 and CD28 (measured by flow cytometry; 
n=6; **p <0.01; ***p<0.001). 
 
Figure 6. Expression of CD39 (A) and CD73 (B) on memory and naïve FoxP3
-
 CD4 T cells in spleens of 
healthy mice (measured by flow cytometry; n=10; ***p<0.001). 
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Figure 7. Expression of CD39 (A) and CD73 (B) on IFN-γ-producing CD4 Tcons from spleens of 
healthy mice (measured by flow cytometry; n=10; ***p<0.001). 
 
Figure 8. Analysis of CD73 expression on CD8 T cells in tumors (A) as well as in spleens (B), lymph 
nodes (C)  and bone marrow (D) of healthy wild type (wt) and Panc02 mice as well as ret tg mice with 
(ret tu) or without tumors (ret) (measured by flow cytometry; n=12; *p<0.05; **p<0.01; ***p<0.001). 
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Figure 9. Analysis of CD39 expression on CD8 T cells in tumors (A), spleens (B), lymph nodes  (C) and 
bone marrow (D) of healthy wild type mice (wt), ret tg mice with (ret tu) or without tumors (ret) as well as 
mice with pancreatic adenocarcinoma (Panc02) (measured by flow cytometry; n=12; *p<0.05; **p<0.01; 
***p<0.001). 
 
Figure 10. Analysis of the expression of CD39 (A) and CD73 (B) on CD4 Tcons from spleens of healthy 
mice after the activation of T cells with antibodies against CD3 and CD28 (measured by flow cytometry; 
n=6; ***p<0.001). 
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Figure 11. Expression of CD39 (A) and CD73 (B) on memory and naïve CD8 T cells in spleens of 
healthy mice (measured by flow cytometry; n=10; **p<0.01; ***p<0.001). 
 
Figure 12. Expression  of CD39 (A) and CD73 (B) on IFN-γ-producing CD8 T cells from spleens of 
healthy mice (measured by flow cytometry; n=10; **p<0.01; ***p<0.001). 
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4.3. Expression of ectonucleotidases on MDSCs 
Since the role of CD39 and CD73 expressed on other immunosuppressive cells remains poorly 
understood, we addressed the question whether MDSCs can also contain the enzymatic cascade 
of adenosine synthesis (Fig. 13). We found that CD39 is constitutively expressed on both MDSC 
subpopulations (monocytic CD11b
+
Ly6C
high
Ly6G
-
 and granulocytic CD11b
+
Ly6C
-/low
Ly6G
+ 
cells) from tumor-bearing mice (Fig. 14A). However, CD73 expression differed between 
granulocytic and monocytic subsets (Fig. 14B-E). In particular, approximately 20% of 
granulocytic IMCs (which are considered MDSC counterparts in healthy mice) expressed CD73, 
whereas on the monocytic IMC subset, CD73 was barely detectable (Fig. 14B, C, E). In contrast, 
Ly6C
-/low 
MDSCs from tumor-bearing mice were highly enriched in CD73
+
 cells (Fig. 14B-D). 
As regards to the monocytic Ly6C
high
 MDSC subset, we found that the percentages of CD73
+
 
cells were slightly increased in spleens and tumors of ret transgenic mice, whereas there was a 
pronounced accumulation of CD73
+
 monocytic MDSCs in Panc02 tumors (Fig. 14E). These data 
indicate that CD73 expression may represent another distinctive marker of MDSCs, and 
adenosine production may serve as a highly regulated mechanism of MDSC-mediated 
immunosuppression.  
Thus, the expression of CD39 and CD73 on a variety of immune and malignant cells as well as 
strong immune suppressive properties of adenosine suggest that this molecule can provide an 
important mechanism of immune regulation and represent an attractive target for therapeutic 
modulation. Therefore, we targeted in ret transgenic melanoma mouse model either adenosine 
synthesis or signaling using a CD73 inhibitor (APCP) or an A2a receptor antagonist (SCH58261) 
respectively (Fig. 15A). Both treatments resulted in a significantly prolonged survival (please 
include median survival for all arms) of melanoma-bearing animals as compared to the non-
treated group (Fig. 15B). To better understand the mechanisms behind the improved survival, we 
focused on the effects of APCP on the anti-tumor immunity. In tumor-bearing mice, we observed 
a substantial reduction in the frequency of MDSCs among tumor infiltrating leukocytes (Fig. 
16A). In addition, we detected a tendency toward increased numbers of IFN--producing CD8 T 
cells in metastatic lymph nodes upon the treatment (Fig. 16B). However, the frequency of T cells 
infiltrating skin tumors or metastatic lymph nodes was not changed.   
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Figure 13. Representative dot plots of the bone marrow from ret tg melanoma-bearing mice showing the 
gating strategy for the analysis of CD73 and CD39 expression on MDSCs (measured by flow cytometry). 
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Figure 14. Expression of CD39 and CD73 on granulocytic and monocytic MDSC subsets detected by 
flow cytometry. (A) Representative histogram showing CD39 expression on BM-derived MDSCs. (B-D) 
Analysis of CD73 expression on granulocytic MDSCs from the bone marrow (B), spleen (C) and tumors 
(D).  (E) Analysis of CD73 expression on monocytic MDSC in lymphoid organs and tumors (n=10. 
*p<0.05; **p<0.01; ***p<0.001). 
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Figure 15. Effect of the selective adenosine A2a receptor antagonist SCH58261 and the CD73 inhibitor 
APCP on the survival of melanoma-bearing transgenic mice. (A) Treatment regimens; (B) ) Survival of 
mice (16 mice/group) is shown as a Kaplan-Meier curve (*p<0.05). 
 
 
Figure 16. Effects of APCP treatment on MDSC frequencies among tumor-infiltrating leukocytes (A) and 
on amounts of IFN--producing CD8 T cells  in metastatic lymph nodes (B) (measured by flow cytometry; 
*p<0.05, n=16).  
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5. Discussion 
The immune system deploys a variety of suppressive mechanisms to restrain excessive responses 
against pathogens or preclude harmful autoimmune reactions (35, 83, 183, 184). However, these 
mechanisms can be hijacked by tumors to subvert anti-cancer immunity or even involve immune 
cells in promoting tumor growth, angiogenesis and metastasis (1, 6, 39, 40, 82, 132, 174, 176, 
185).  
Extracellular adenosine is a small molecule, regulating the function of diverse immune cell 
populations and playing an important role in maintaining the balance between inflammation and 
tolerance (82, 186). Under homeostatic conditions, adenosine levels in tissues are relatively low 
(187). However, at the peak of inflammation, the destruction of host tissues by a vigorous 
immune response combined with damaged microcirculation and hypoxia set off multiple 
pathways, leading to the accumulation of adenosine in the extracellular space (187). Enhanced 
adenosine signaling prevents further tissue destruction by inhibiting the effector arm of the 
ongoing immune response. Tumors are often characterized by hypoxia and severe tissue damage, 
which trigger adenosine accumulation in the microenvironment and ultimately lead to the 
inhibition of an anti-tumor immunity (188). Adenosine receptors are expressed on a wide variety 
of immune cells (82), which makes them subject to adenosine-mediated regulation. Activation of 
adenosine receptors triggers accumulation of cAMP in target cells, leading to a profound 
alteration in their activity (82, 188). In particular, the engagement of adenosine receptors on 
effector T cells and resulting cAMP accumulation strongly inhibits their activation, function and 
proliferation (82, 188).  
One of the main pathways, leading to adenosine accumulation outside the cell is the two-step 
hydrolysis of extracellular ATP by ectonucleotidases CD39 and CD73 (186). These proteins have 
been detected on various populations of immune cells as well as on tumor cells. In contrast to 
many other enzymes, CD39 and CD73 lack regulatory domains. Therefore, their net activity 
depends on their expression and the concentrations of the substrate, product and bivalent cations 
(129, 189-192). Importantly, CD73 is inhibited by high concentrations of ATP or ADP, 
underscoring the highly coordinated action of CD39 and CD73 (191). Ectonucleotidases play an 
important role in the regulation of the balance between the proinflammatory ATP and 
immunosuppressive adenosine.   However,  the  specific  contribution  of  particular  immune cell  
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populations to the accumulation of extracellular adenosine is still poorly understood. Moreover, it 
is remains unclear whether adenosine produced by these enzymes acts in an autocrine or 
paracrine manner. In the current study, we addressed these questions by analyzing the patterns of 
ectonucleotidase expression on various immune cell subsets in the context of their phenotype.  
5.1 Expression of ectonucleotidases on murine Tregs, Tcons and CD8 T cells 
Previous studies suggested that extracellular adenosine production represents a major mechanism 
of Treg-mediated immune suppression (82, 83). Therefore, we decided to analyze the distribution 
of ectonucleotidases on Tregs from tumors and lymphoid organs to determine if adenosine 
production is a ubiquitous and constitutive function of Tregs and if its intensity could vary 
between different lymphoid organs and the tumor site. We found that, both in lymphoid organs 
and tumors, ectonucleotidases were expressed on the majority of Tregs, although we observed 
substantial differences between Tregs in spleens and tumors of mice with melanoma and 
pancreatic cancer. In particular, only 60% of Tregs from melanoma lesions of ret transgenic mice 
were CD39
+
CD73
+
, whereas more than 90% of Tregs from spleens and Panc02 tumors expressed 
both enzymes. Moreover, the levels of CD73 on Tregs from spleens of tumor-bearing ret 
transgenic mice were substantially lower than in non-transgenic littermates. These data suggest 
that ectonucleotidase expression on Tregs is neither constitutive nor ubiquitous, and Tregs from 
the tumor may strongly differ from Tregs in lymphoid organs in terms of their ability to produce 
adenosine. This indicates that adenosine production by Tregs can be negatively regulated by the 
tumor microenvironment. 
Another important observation made in the same set of experiments was that ectonucleotidase 
expression is not restricted to the regulatory compartment of T cells. Although very few Tcons 
and CD8 T cells from the spleen coexpressed CD39 and CD73, their tumor-infiltrating 
counterparts were distinctly enriched in CD39
+
CD73
+ 
cells. However, despite the low proportion 
of CD8 T cells expressing both enzymes, CD73 was ubiquitously expressed on the vast majority 
of CD8 T cells from lymphoid organs and tumors, suggesting that CD8 T cells may constitutively 
convert the environmental AMP into adenosine and prevent their own inappropriate activation. 
On the other hand, this might represent a homeostatic mechanism of maintaining CD8 T cell 
turnover, proliferation and survival at constant rates, since adenosine signaling has been shown to 
regulate all these processes (82, 83).  
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In contrast to the ubiquitously expressed CD73, the expression of CD39 varied significantly 
between lymphoid organs and tumor tissues as well as between healthy and tumor-bearing 
animals. Although in spleens and lymph nodes the percentage of CD39
+ 
cells was relatively low 
(around 5-10%), the CD8 T cell compartment in the bone marrow contained more than 30% or 
even up to 50% (in the Panc02 model) of CD39-expressing cells. Since the T cell pool in the 
bone marrow is largely comprised of memory cells, this led us to a hypothesis that 
ectonucleotidases might be involved in the function of these cells.  
Collectively, these observations suggested a previously unappreciated role of CD39 and CD73 
expression on effector T cells in the regulation of anti-tumor immunity and implied possible 
mechanisms of autocrine adenosine signaling in non-regulatory T cells.  
5.2 Patterns of ectonucleotidase expression on Tregs and Tcons from the peripheral 
blood of cancer patients and healthy donors 
To understand if the data on ectonucleotidase expression obtained in mouse models could be of 
relevance for the human immune system, we analyzed the expression of CD39 and CD73 in the 
peripheral blood of melanoma patients and healthy donors. We found that CD39 and CD73 
expression on human Tregs and Tcons strongly varied not only among patients but also in healthy 
donors. Between some individuals, the differences in frequencies of CD39
+
 or CD73
+
 populations 
were more than ten-fold.  Furthermore, the patterns of ectonucleotidase expression on human 
CD4 T cells showed little similarity to those observed in mice. In particular, the mean frequency 
of CD39
+
 cells among human Tregs was around 50%. Moreover, CD73 was absent from the 
majority of Tregs. This was in agreement with the report by Mandapathil et al. (93), showing the 
lack of CD73 on Treg surface. Thus, most Tregs from human peripheral blood lack the enzymatic 
machinery that performs the two step conversion of extracellular ATP into adenosine. Therefore, 
the function of human Tregs is probably restricted to the hydrolysis of the pro-inflammatory 
ATP. In melanoma patients, we observed a significant expansion of the CD39
+
 subpopulation of 
Tregs, which might reflect the enhanced capacity of Tregs to decrease ATP levels in the 
peripheral blood and thereby dampen the inflammation. 
In contrast to Tregs, only 5-10% of human Tcons expressed CD39. The frequency of such cells 
doubled in patients with pancreatic cancer, compared to healthy donors. As regards to CD73, this 
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enzyme was expressed on 10-20% of Tcons from the peripheral blood. Notably, the percentage of 
CD73
+
 cells in Tcons from melanoma patients was two times larger than in healthy donors. 
Thus, ectonucleotidase expression on regulatory and conventional T cells is substantially 
increased in cancer patients, which may lead to an enhanced adenosine accumulation and 
contribute to the tumor associated immune suppression.  
5.3 Activation-dependent induction of ectonucleotidases on T cells 
To gain a better understanding of mechanisms governing ectonucleotidase expression on non-
regulatory T cells, we investigated the patterns of CD39 and CD73 expression, depending on the 
phenotype, activation status and functional activity of T cells. We hypothesized that 
ectonucleotidases on Tcons and CD8 T cells might serve two distinct functions: 1) keep resting T 
cells in check by preventing an inappropriate activation; 2) provide an autocrine negative 
feedback loop to restrain a T cell response, once T cells have been activated. This would suggest 
that similar to CTLA-4 and PD-1 molecules, ectonucleotidases represent an immune checkpoint 
maintaining tolerance and regulating the duration and intensity of the immune response (6). 
Accordingly, we found that the CD25
+
 subset of Tcons, presumably representing activated T cells 
(35), contain significantly higher percentages of CD39
+
 and CD73
+
 cells than their resting CD25
-
 
counterparts both in lymphoid organs (bone marrow, spleen, lymph nodes) and tumors. This was 
the case both for healthy and tumor-bearing animals. Notably, we observed that even resting 
CD25
-
 Tcons in the bone marrow were highly enriched in CD39
+
 and CD73
+
 cells.  
In addition, we observed that in pancreatic tumors, CD73 was expressed by virtually all Tcons, 
both CD25
+
 and CD25
-
. Moreover, CD39 was also expressed on a considerably higher proportion 
of Tcons than in spleens or lymph nodes. This indicates that microenvironmental factors might 
also induce ectonucleotidase expression, even on resting T cells. Indeed, we previously showed 
that Panc02 tumors contain increasingly high amounts of the immunosuppressive cytokine TGF-
Furthermore, several recent studies demonstrated that this cytokine might be a major inducer 
of the ectonucleotidase expression on T cells. In particular, Chalmin et al. (193) showed that T 
cell polarization under the Th17-skewing conditions (the activation in the presence of TGF-and 
IL-6), triggered the ectonucleotidase expression and adenosine production. The results obtained 
in that study suggested the necessity of both TGF-and IL-6 for the upregulation of the 
ectonucleotidase expression. Remarkably, the authors showed that Th17 cells suppressed antigen-
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specific T cell proliferation and function in an ectonucleotidase-dependent manner in vitro and in 
vivo. However, Regateiro et al. (194) demonstrated that TGF-alone is sufficient for an 
activation-dependent upregulation of CD39 and CD73 both in FoxP3
+
 and FoxP3
-
 CD4 T cells. 
Importantly, de novo ectonucleotidase induction proved independent of FoxP3. Moreover, this 
study showed that CD73 is expressed on about 80% of CD8 T cells. Similarly to Tcons, activated 
CD8 T cells displayed a TGF--dependent upregulation of CD73 levels and a strong increase in 
the frequency of CD39
+
 cells. Interestingly, although CD39 expression on CD8 T cells could be 
induced de novo by activation alone, the presence of TGF-substantially increased the 
expression of the enzyme. In contrast to the results reported by Chalmin et al. (193), the study by 
Regaterio et al.  (194) suggested that inflammatory cytokines, in particular IL-6, can antagonize 
the ectonucleotidase induction. Altogether, the results of these two studies suggested that 
activation signals and TGF- strongly affect the ectonucleotidase expression on T cells. 
Therefore, we next analyzed the impact of activation on the expression of CD39 and CD73. To 
this end, we stimulated splenocytes from healthy mice through the engagement of CD3 and 
CD28. Since we sought to determine the net effect of activation on ectonucleotidase expression, 
we did not add any polarizing cytokines. In contrast to the report of Regaterio et al. (194), we 
observed no significant difference in the percentage of CD73
+
 T cells between the activated and 
intact cells. This apparent discrepancy between our ex vivo (increased percentage of CD73
+
 cells 
among CD25
+
 Tcons) and in vitro findings may be due to the artificial and non-physiological 
conditions of an in vitro T cell activation, which cannot recapitulate the in vivo TCR stimulation. 
However, in line with the study by Regaterio et al. (194) and our own ex vivo data, we found that 
the frequencies of CD39
+
 cells among both CD4 and CD8 T cells significantly increased upon 
activation. It has been shown that activated T cells release increased amounts of ATP in order to 
promote their own activation through autocrine purinergic signaling (186, 195). Indeed, T cells 
express both ionotropic (P2X) and metabotropic (P2Y) ATP receptors (186). Recently, Schenk et 
al. (196) demonstrated that the TCR stimulation triggered a release of cellular ATP through 
pannexin-1 channels. Pannexin-1 translocates to the immune synapse where it releases ATP, 
which provides an autocrine positive feedback loop amplifying T cell activation (196). However, 
high concentration of extracellular ATP may trigger apoptosis of T cells (82). Therefore the 
mechanisms to dispose of excessive ATP are necessary. The rapid induction of CD39 upon the T 
cell activation may provide an effective means of controlling extracellular ATP levels during the 
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course of the T cell response. Furthermore, CD73 induction in activated T cells may dampen their 
function through accumulation of extracellular adenosine. For instance, the data of Romio et al. 
(90) indicated that NF-B signaling (a major signaling pathway triggered by T cell activation) in 
stimulated T cells is regulated by the activity of CD73. A knockdown or inhibition of CD73 
resulted in an augmented release of the pro-inflammatory cytokines IL-2, TNF- and IFN-
Thus, the rapid induction of CD39 and CD73 upon TCR stimulation may have profound effects 
on the development of the T cell response. In particular, CD39 can serve to degrade the excess of 
ATP released upon activation, thereby fine-tuning the stimulatory signals and preventing T cell 
apoptosis. Moreover, since the released ATP can also affect bystander cells such as DCs or NK 
cells, the activity of CD39 on activated T cells might also modulate the function of a local 
network of immune cells. In addition, the cleavage of ATP by CD39 yields AMP which is the 
substrate of CD73. Therefore, an activation-triggered CD39 induction on T cells can also increase 
the rate of adenosine production leading to the suppression of T cell functions. This can be 
ensured by the concomitant upregulation of CD73 on the same cells.  
5.4 Ectonucleotidases on memory T cells  
Immunological memory constitutes an essential feature of adaptive immunity, whereby an 
organism „remembers‟ the original pathogen encountered and mounts more robust humoral and 
cellular responses to rapidly control reinfection and reduce the severity of disease (184). 
Compared to naïve lymphocytes, memory T and B cells display increased longevity and they do 
not require costimulatory signals for their activation (184). 
Memory T cells develop from naive T cells after a stimulation with cognate antigen and exert a 
rapid and vigorous response to the previously encountered antigen (183, 184). The memory T cell 
compartment comprises two main subsets: central memory T cells and effector memory T cells 
(184). Central memory T cells express CD62L (L-selectin) and the CC-chemokine receptor 7 
(CCR7), which enables them to circulate through lymphoid organs. In contrast, effector memory 
T cells lack both CD62L and CCR7, and they circulate in non-lymphoid tissues. In addition, 
these cells express high levels of effector molecules such as cytokines or granzyme B and 
perforin, which allows them to rapidly exert effector functions upon activation (184). However, 
despite numerous studies conducted over the last decades, the mechanisms governing the 
development and homeostasis of memory lymphocytes are still largely obscure.     
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Since extracellular adenosine profoundly dampens T cell activation, we hypothesized that it may 
also play a role in the regulation of T cell memory and effector function. To test this supposition, 
we evaluated the CD39 and CD73 expression on naïve as well as central and effector memory 
CD4 and CD8 T cells.  We found that central and especially effector memory T cells (both Tcons 
and CD8) were highly enriched in CD39-expressing cells. The same pattern was observed for 
CD4 T cells in the case of CD73 expression, whereas all three CD8 T cell subsets were mostly 
comprised of CD73
+
 cells. Next, we sought to determine if these correlations of ectonucleotidase 
with the T cell phenotype may have some functional implications. Since the rapid production of 
effector molecules upon stimulation is a cardinal feature of memory cells (197), we analyzed the 
expression of CD39 and CD73 on CD4 and CD8 T cells in the context of their ability to produce 
IFN-a cytokine driving the Th1-type response (198). We found that both CD4 and CD8 T cells 
that rapidly produced IFN-after restimulation contained a higher percentage of 
ectonucleotidase-expressing cells as compared to the population unable to produce IFN- 
Thus, we showed that ectonucleotidase expression in T cells is largely associated with the 
memory compartment. Therefore, memory cells might constitutively produce adenosine from 
ATP to prevent their adverse activation and an outbreak of destructive autoimmunity. In this 
regard, it is logical that the effector memory subset contains a higher frequency of 
ectonucleotidase-expressing cells than the central memory cell population, since an inappropriate 
or unspecific activation of effector memory cells might entail more immediate and severe 
damages than those of central memory cells. In the same way, the increased percentage of 
ectonucleotidase-expressing subsets in IFN--producing T cells subpopulations might be essential 
for controlling the activity of these cells through autrocrine adenosine signaling. 
5.5 The role of ectonucleotidases on MDSCs 
The heterogeneous population of MDSCs exploits a vast array of mechanisms to suppress the 
anti-tumor immunity (132). Some of these mechanisms are shared by all MDSC fractions while 
others are rather restricted to specific MDSC subsets (39, 40). Each of these suppressive 
pathways profoundly inhibits the activation, proliferation, migration and effector functions of T 
cells.     
It has previously been demonstrated that autocrine purinergic signaling plays an important role in 
the regulation of myeloid cell chemotaxis (186, 199-202). For instance, ectonucleotidases have 
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been shown to regulate neutrophil chemotaxis by converting extracellular ATP into adenosine 
(201). Upon their activation with bacterial formylated peptides, neutrophils release ATP through 
pannexin-1 hemichannels (199, 200). ATP signaling through P2Y2 receptors augments the 
neutrophil activation and enhances their sensitivity to chemotactic gradients (186, 199, 200). 
Moreover, P2Y2-signaling triggers cell polarization within the gradient field and induces the 
translocation of pannexin-1, ectonucleotidases and A3 receptors to the leading edge of the cell 
(186, 199-201). The clustering of these proteins focuses ATP release and adenosine production at 
the leading edge and results in the autocrine signaling through A3 receptors, promoting cell 
migration towards the source of chemoattractants (186, 199-201). 
A recent study by Ryzhov et al. (151) suggested that both auto- and paracrine purinergic 
signaling substantially contribute to the MDSC function. First, the authors detected CD73 on in 
vitro differentiated MDSCs. The expression of CD73 on a per-cell level was the highest in the 
CD11b
+
Gr1
high
 subset followed by the CD11b
+
Gr1
int
 and CD11b
+
Gr1
low
 fractions. Importantly, 
the expression of CD73 on the in vitro differentiated MDSCs positively correlated with its 
enzymatic activity. This was in line with the analyses of CD73 crystal structure and ex vivo 
assays showing that the activity of CD73 depends primarily on its expression and the 
substrate/product ratio and can be described by conventional Michaelis-Menten kinetics (129, 
189-192). Furthermore, Ryzhov et al. (151) showed that A2BR-signaling strongly augments the 
expansion and immunosuppressive activity of CD11b
+
Gr1
high
 cells both in vitro and in vivo. This 
implied that adenosine production by MDSCs contributes to their suppressive properties in a dual 
manner. On one hand, it can modulate the activity of other cells in the local microenvironment, 
inhibiting effector T cells and promoting Tregs through the accumulation of intracellular cAMP. 
On the other hand, autocrine adenosine production can increase the numbers and activity of 
granulocytic MDSCs. However, this study demonstrated only CD73 expression and activity on 
MDSCs that were differentiated in vitro. Furthermore, CD39 expression on MDSCs was not 
investigated.  
Therefore, we asked if these findings are relevant to the in vivo situation. To this end, we studied 
the expression of CD39 and CD73 on MDSCs from tumor-bearing mice, as well as on 
CD11b
+
Gr1
+ 
IMCs from healthy animals. Since the granulocytic (Ly6G
high
Ly6C
low/-
) and 
monocytic  (Ly6G
-
Ly6C
high
)  subsets  of  MDSCs have been shown to differ  in  their suppressive  
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mechanisms, we separately analyzed the ectonucleotidase expression in each of these subsets. We 
observed that both IMCs and MDSCs constitutively and ubiquitously express CD39, suggesting 
that all such cells have the capacity to hydrolyze ATP. This corresponds to the findings indicating 
the important role of CD39 in myeloid cell migration and function (186, 199-203). In contrast, 
CD73 expression showed considerable heterogeneity. Analyzing the granulocytic subset of 
CD11b
+
Gr1
+ 
cells, we found that IMCs from the spleen and bone marrow contained a substantial 
population of CD73-expressing cells. However, MDSCs from respective lymphoid organs 
harbored distinctly higher percentages of CD73
+
 cells. This could be linked to the observed 
expansion of CD11b
+
Gr1
+ 
cells in both tumor models (168; Karakhanova et al., upublished data). 
Therefore, these data suggest that ectonucleotidases not only contributes to MDSC suppressive 
function but can also promote MDSC expansion through autocrine signaling. 
Granulocytic MDSCs both from melanoma lesions and pancreatic tumors were also highly 
enriched in CD73
+
 cells. Given the high numbers of tumor-infiltrating granulocytic MDSCs in 
both models (168), these cells can contribute to the accumulation of extracellular adenosine in the 
tumor microenvironment. Of note, we observed a particularly high frequency of CD73
+
 cells 
among the granulocytic MDSCs from Panc02 tumors. These tumors contain high levels of TGF-
β, which has been shown to induce CD73 expression on T cells through the downregulation of 
the transcription factor Gfi-1 (193). It has been reported that this factor plays in important role in 
the differentiation of neutrophils and its genetic ablation leads to the expansion of immature 
CD11b
+
Gr1
+ 
cells (204). Therefore, the abundance of TGF-β may account for the high frequency 
of the CD73
+
 granulocytic MDSCs as well as for the overall expansion of MDSCs in Panc02 
tumors.  
As regards to the monocytic subset of MDSCs, we showed that only a minor proportion (less than 
10%) of these cells expressed CD73
+
. In contrast, the CD73
+
 subset comprised up to 40% of the 
monocytic MDSCs in Panc02 tumors, which might also be a consequence of the high TGF-β 
levels in the tumor microenvironment. Thus, we showed that MDSCs are highly enriched in 
CD73-expressing cells, as compared to CD11b
+
Gr1
+ 
IMC, and CD73 expression is largely 
restricted to the granulocytic MDSC subset. In addition, the CD73 expression can be induced on 
tumor-infiltrating monocytic MDSCs.  
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Since MDSCs have previously been shown to strongly suppress the anti-tumor response in ret 
transgenic mice (168), we asked if the inhibition of the CD73 activity in vivo might hamper 
MDSC expansion and function, thereby restoring anti-tumor immune responses. To this end, we 
treated ret transgenic tumor-bearing mice with a CD73 inhibitor APCP and analyzed its effects 
on the survival and the immune system. Similarly to previous studies based on transplantable 
mouse tumor models (127, 129, 131, 205), the treatment significantly improved the survival of 
tumor-bearing animals. In addition, this therapy substantially reduced the frequency of MDSCs 
among tumor-infiltrating leukocytes, suggesting a possible role of adenosine signaling in the 
MDSC expansion. However, the treatment had no statistically significant effects on T cell 
frequencies in tumor lesions or lymphoid organs, on the TCR -chain expression in these cells or 
on the IFN- production by these T cells. Therefore, the beneficial effect of the therapy can be 
partly due to the decrease in the numbers of MDSCs since the latter lave been shown to directly 
promote tumor development, metastasis and angiogenesis (39). However, other effects of the 
CD73 inhibitor APCP cannot be excluded and need further investigation. 
To summarize, we showed that CD39 and CD73 are highly expressed by murine regulatory T 
cells. However, on human Tregs these ectonucleotidases are expressed to the less extent than on 
mouse cells. We have also detected ectonucleotidase expression on CD4
+
FoxP3
-
 conventional T 
cells and CD8 T cells. Importantly, CD25
+
 Tcon, tumor-infiltrating T cells and memory T cells 
were all highly enriched in CD39
+
 and CD73
+
 cells, which implies an important role of 
ectonucleotidases in the regulation of T cell activation, effector function and memory.  
Furthermore, we demonstrated for the first time that the majority of granulocytic MDSCs 
coexpress CD39 and CD73, which suggests that the production of extracellular adenosine might 
contribute to MDSC immunosuppressive properties. Finally, using a clinically relevant ret 
transgenic model of melanoma we showed that the inhibition of adenosine production or 
signaling prolonged survival of tumor-bearing mice and reduced MDSC infiltration into tumors, 
indicating that this might be a promising strategy for cancer therapy. 
  
 
 
76 
 
REFERENCES 
1. Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: integrating immunity's 
roles in cancer suppression and promotion. Science 331: 1565-70 
2. Clark WH, Jr., Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, 
Halpern AC. 1989. Model predicting survival in stage I melanoma based on tumor 
progression. J Natl Cancer Inst 81: 1893-904 
3. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. 1998. CD8+ T 
cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. 
Cancer Res 58: 3491-4 
4. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. 2013. Suppression, subversion and 
escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 171: 36-45 
5. Trinchieri G. 2012. Cancer and inflammation: an old intuition with rapidly evolving new 
concepts. Annu Rev Immunol 30: 677-706 
6. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat 
Rev Cancer 12: 252-64 
7. Restifo NP, Dudley ME, Rosenberg SA. 2012. Adoptive immunotherapy for cancer: 
harnessing the T cell response. Nat Rev Immunol 12: 269-81 
8. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. 
1993. Identification of human cancers deficient in antigen processing. J Exp Med 177: 
265-72 
9. Hadrup S, Donia M, Thor Straten P. 2012. Effector CD4 and CD8 T Cells and Their Role 
in the Tumor Microenvironment. Cancer Microenviron  
10. Mendez R, Aptsiauri N, Del Campo A, Maleno I, Cabrera T, Ruiz-Cabello F, Garrido F, 
Garcia-Lora A. 2009. HLA and melanoma: multiple alterations in HLA class I and II 
expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol 
Immunother 58: 1507-15 
11. Offringa R. 2009. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol 
21: 190-9 
12. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, 
Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White 
DE, Dudley ME. 2011. Durable complete responses in heavily pretreated patients with 
metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17: 4550-7 
13. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, 
Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, 
Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. 2011. 
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using 
genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-24 
14. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, 
Knuth A, Boon T. 1991. A gene encoding an antigen recognized by cytolytic T 
lymphocytes on a human melanoma. Science 254: 1643-7 
15. Overwijk WW, Restifo NP. 2000. Autoimmunity and the immunotherapy of cancer: 
targeting the "self" to destroy the "other". Crit Rev Immunol 20: 433-50 
16. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, 
Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. 2010. Eradication 
of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells 
genetically engineered to recognize CD19. Blood 116: 4099-102 
17. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, 
Rosenberg SA. 1994. Cloning of the gene coding for a shared human melanoma antigen 
recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91: 
3515-9 
 
 
77 
 
18. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, 
Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, 
Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, 
Nathan DA, Laurencot CM, Rosenberg SA. 2009. Gene therapy with human and mouse 
T-cell receptors mediates cancer regression and targets normal tissues expressing 
cognate antigen. Blood 114: 535-46 
19. Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong 
WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB. 
2009. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte 
immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116: 981-9 e1 
20. Davies MA, Samuels Y. 2010. Analysis of the genome to personalize therapy for 
melanoma. Oncogene 29: 5545-55 
21. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, 
White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, 
Smyth MJ, Old LJ, Mardis ER, Schreiber RD. 2012. Cancer exome analysis reveals a T-
cell-dependent mechanism of cancer immunoediting. Nature 482: 400-4 
22. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. 1996. 
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor 
infiltrating lymphocytes. J Exp Med 183: 1185-92 
23. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji 
S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, 
Simpson AJ, Old LJ, Hide W. 2008. Genome-wide analysis of cancer/testis gene 
expression. Proc Natl Acad Sci U S A 105: 20422-7 
24. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, 
Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White 
SL, Simpson AJ, Old LJ, Camargo AA, Vasconcelos AT. 2009. CTdatabase: a 
knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic 
Acids Res 37: D816-9 
25. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. 2005. Cancer/testis antigens, 
gametogenesis and cancer. Nat Rev Cancer 5: 615-25 
26. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. 2011. The prognostic 
influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-
analysis. Br J Cancer 105: 93-103 
27. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, 
Thompson JF. 2012. Tumor-infiltrating lymphocyte grade is an independent predictor of 
sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin 
Oncol 30: 2678-83 
28. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. 2011. 
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 
71: 5601-5 
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini 
M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, 
Fridman WH, Pages F. 2006. Type, density, and location of immune cells within human 
colorectal tumors predict clinical outcome. Science 313: 1960-4 
30. Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. 2009. 
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J 
Clin Invest 119: 2245-56 
31. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. 2010. Regulatory 
T cells in cancer. Adv Cancer Res 107: 57-117 
32. Klebanoff CA, Gattinoni L, Restifo NP. 2006. CD8+ T-cell memory in tumor immunology 
and immunotherapy. Immunol Rev 211: 214-24 
 
 
78 
 
33. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. 2011. Relationship between the 
expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell 
carcinoma. Oral Oncol 47: 1148-53 
34. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao 
YS, Xu Y, Fan J. 2009. Overexpression of PD-L1 significantly associates with tumor 
aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin 
Cancer Res 15: 971-9 
35. Josefowicz SZ, Lu LF, Rudensky AY. 2012. Regulatory T cells: mechanisms of 
differentiation and function. Annu Rev Immunol 30: 531-64 
36. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. 2010. FOXP3+ regulatory T cells in 
the human immune system. Nat Rev Immunol 10: 490-500 
37. Badoual C, Hans S, Fridman WH, Brasnu D, Erdman S, Tartour E. 2009. Revisiting the 
prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 27: e5-6; 
author reply e7 
38. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. 2011. Targeting regulatory T cells in 
cancer. Cancer Res 71: 6915-20 
39. Umansky V, Sevko A. 2012. Tumor Microenvironment and Myeloid-Derived Suppressor 
Cells. Cancer Microenviron  
40. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. 2012. Coordinated regulation of myeloid 
cells by tumours. Nat Rev Immunol 12: 253-68 
41. Erdman SE, Rao VP, Olipitz W, Taylor CL, Jackson EA, Levkovich T, Lee CW, Horwitz 
BH, Fox JG, Ge Z, Poutahidis T. 2010. Unifying roles for regulatory T cells and 
inflammation in cancer. Int J Cancer 126: 1651-65 
42. Erdman SE, Poutahidis T. 2010. Cancer inflammation and regulatory T cells. Int J 
Cancer 127: 768-79 
43. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, 
Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E. 2006. Prognostic value 
of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer 
Res 12: 465-72 
44. Campbell DJ, Koch MA. 2011. Phenotypical and functional specialization of FOXP3+ 
regulatory T cells. Nat Rev Immunol 11: 119-30 
45. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, 
Marcheteau E, Quillien VR, Banissi C, Carpentier A, Sandoval F, Nizard M, Quintin-
Colonna F, Kroemer G, Fridman WH, Zitvogel L, Oudard SP, Tartour E. 2012. 
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. 
Oncoimmunology 1: 326-33 
46. Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, 
Kroemer G, Tartour E. 2012. Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, 
Mechanism of Expansion In Situ and Clinical Significance. Cancer Microenviron  
47. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. 
2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat 
Immunol 6: 1219-27 
48. Kretschmer K, Heng TS, von Boehmer H. 2006. De novo production of antigen-specific 
suppressor cells in vivo. Nat Protoc 1: 653-61 
49. Verginis P, McLaughlin KA, Wucherpfennig KW, von Boehmer H, Apostolou I. 2008. 
Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets 
of suppression. Proc Natl Acad Sci U S A 105: 3479-84 
50. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, Peterson DA, 
Stappenbeck TS, Hsieh CS. 2011. Peripheral education of the immune system by colonic 
commensal microbiota. Nature 478: 250-4 
 
 
79 
 
51. Davidson TS, DiPaolo RJ, Andersson J, Shevach EM. 2007. Cutting Edge: IL-2 is 
essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol 178: 
4022-6 
52. Burchill MA, Yang J, Vang KB, Moon JJ, Chu HH, Lio CW, Vegoe AL, Hsieh CS, Jenkins 
MK, Farrar MA. 2008. Linked T cell receptor and cytokine signaling govern the 
development of the regulatory T cell repertoire. Immunity 28: 112-21 
53. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, 
Siegel R, Hennighausen L, Shevach EM, O'Shea J J. 2007. Interleukin-2 signaling via 
STAT5 constrains T helper 17 cell generation. Immunity 26: 371-81 
54. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. 2005. A function for interleukin 2 
in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142-51 
55. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. 2006. 
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 
212: 28-50 
56. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. 
1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents 
colitis. Nature 389: 737-42 
57. Shalev I, Schmelzle M, Robson SC, Levy G. 2011. Making sense of regulatory T cell 
suppressive function. Semin Immunol 23: 282-92 
58. Zhou G, Levitsky HI. 2007. Natural regulatory T cells and de novo-induced regulatory T 
cells contribute independently to tumor-specific tolerance. J Immunol 178: 2155-62 
59. Bilate AM, Lafaille JJ. 2012. Induced CD4+Foxp3+ regulatory T cells in immune 
tolerance. Annu Rev Immunol 30: 733-58 
60. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. 2010. Role of 
conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 
463: 808-12 
61. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, Umetsu DT, Rudensky 
AY. 2012. Extrathymically generated regulatory T cells control mucosal TH2 
inflammation. Nature 482: 395-9 
62. Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. 2012. Extrathymic 
generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. 
Cell 150: 29-38 
63. Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, Huehn J, Hori S. 
2012. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in 
conventional T cells but not reprogramming of regulatory T cells. Immunity 36: 262-75 
64. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, 
Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone 
JA. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of 
human CD4+ T reg cells. J Exp Med 203: 1701-11 
65. Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, Bacchetta R, Naldini L, 
Roncarolo MG, Soudeyns H, Levings MK. 2008. Generation of potent and stable human 
CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16: 
194-202 
66. Simonetta F, Chiali A, Cordier C, Urrutia A, Girault I, Bloquet S, Tanchot C, Bourgeois C. 
2010. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J 
Immunol 40: 2528-38 
67. Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rotzschke O, Falk K. 
2009. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating 
effector cells. Blood 113: 827-36 
 
 
 
80 
 
68. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. 2008. 
Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg 
expansion, and Treg cryopreservation. PLoS One 3: e3161 
69. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, Sakaguchi S. 
2007. Control of immune responses by antigen-specific regulatory T cells expressing the 
folate receptor. Immunity 27: 145-59 
70. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. 2007. CD4+CD25+Foxp3+ 
regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T 
cells. Nat Immunol 8: 1353-62 
71. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. 1999. Cutting edge: 
lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J 
Immunol 163: 1128-31 
72. Miyara M, Sakaguchi S. 2007. Natural regulatory T cells: mechanisms of suppression. 
Trends Mol Med 13: 108-16 
73. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V, Bonanno G, 
Rutella S, Durelli I, Horenstein AL, Fiore F, Massaia M, Colombo MP, Baccarani M, 
Lemoli RM. 2007. Modulation of tryptophan catabolism by human leukemic cells results 
in the conversion of CD25- into CD25+ T regulatory cells. Blood 109: 2871-7 
74. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, 
Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA. 2004. Role of 
LAG-3 in regulatory T cells. Immunity 21: 503-13 
75. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, Flores M, Li N, 
Schweighoffer E, Greenberg S, Tybulewicz V, Vignali D, Clynes R. 2008. Regulatory T 
cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. 
J Immunol 180: 5916-26 
76. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino 
CJ, Clark H, Eaton D, Grogan JL. 2009. The surface protein TIGIT suppresses T cell 
activation by promoting the generation of mature immunoregulatory dendritic cells. Nat 
Immunol 10: 48-57 
77. von Boehmer H. 2005. Mechanisms of suppression by suppressor T cells. Nat Immunol 
6: 338-44 
78. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, 
Roers A, Henderson WR, Jr., Muller W, Rudensky AY. 2008. Regulatory T cell-derived 
interleukin-10 limits inflammation at environmental interfaces. Immunity 28: 546-58 
79. Marie JC, Liggitt D, Rudensky AY. 2006. Cellular mechanisms of fatal early-onset 
autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta 
receptor. Immunity 25: 441-54 
80. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker 
M, Kubach J, Schmitt S, Stoll S, Schild H, Staege MS, Stassen M, Jonuleit H, Schmitt E. 
2007. Cyclic adenosine monophosphate is a key component of regulatory T cell-
mediated suppression. J Exp Med 204: 1303-10 
81. Allard B, Turcotte M, Stagg J. 2012. CD73-generated adenosine: orchestrating the 
tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012: 485156 
82. Stagg J, Smyth MJ. 2010. Extracellular adenosine triphosphate and adenosine in cancer. 
Oncogene 29: 5346-58 
83. Beavis PA, Stagg J, Darcy PK, Smyth MJ. 2012. CD73: a potent suppressor of antitumor 
immune responses. Trends Immunol 33: 231-7 
84. Fredholm BB, Chern Y, Franco R, Sitkovsky M. 2007. Aspects of the general biology of 
adenosine A2A signaling. Prog Neurobiol 83: 263-76 
 
 
 
81 
 
85. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, 
Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I, Dikov MM. 2008. Adenosine 
receptors in regulation of dendritic cell differentiation and function. Blood 112: 1822-31 
86. Majumdar S, Aggarwal BB. 2003. Adenosine suppresses activation of nuclear factor-
kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 22: 
1206-18 
87. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell 
S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M. 2006. A2A 
adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 
103: 13132-7 
88. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, 
Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. 2007. Adenosine generation 
catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune 
suppression. J Exp Med 204: 1257-65 
89. Whiteside TL, Mandapathil M, Schuler P. 2011. The role of the adenosinergic pathway in 
immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem 18: 
5217-23 
90. Romio M, Reinbeck B, Bongardt S, Huls S, Burghoff S, Schrader J. 2011. Extracellular 
purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff 
cells. Am J Physiol Cell Physiol 301: C530-9 
91. Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, Vandenabeele P, 
Nunez G. 2007. Pannexin-1-mediated recognition of bacterial molecules activates the 
cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26: 433-43 
92. Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. 2009. Purinergic signalling 
in the nervous system: an overview. Trends Neurosci 32: 19-29 
93. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, 
Jackson EK, Gorelik E, Whiteside TL. 2010. Generation and accumulation of 
immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J 
Biol Chem 285: 7176-86 
94. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. 2012. Regulatory T cells in 
melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13: e32-42 
95. Le DT, Jaffee EM. 2012. Regulatory T-cell modulation using cyclophosphamide in 
vaccine approaches: a current perspective. Cancer Res 72: 3439-44 
96. Polak L, Turk JL. 1974. Reversal of immunological tolerance by cyclophosphamide 
through inhibition of suppressor cell activity. Nature 249: 654-6 
97. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee 
EM. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor 
immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-
cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-97 
98. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, 
Solary E, Bonnotte B, Martin F. 2004. CD4+CD25+ regulatory T cells suppress tumor 
immunity but are sensitive to cyclophosphamide which allows immunotherapy of 
established tumors to be curative. Eur J Immunol 34: 336-44 
99. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, 
Schneeweiss A, Beckhove P, Schuetz F. 2012. Metronomic cyclophosphamide treatment 
in metastasized breast cancer patients: immunological effects and clinical outcome. 
Cancer Immunol Immunother 61: 353-62 
100. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. 2005. 
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune 
response by low-dose cyclophosphamide. Blood 105: 2862-8 
 
 
 
82 
 
101. Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, 
Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, 
Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C. 2013. Effects of 
cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in 
melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific 
T cell response. Cancer Immunol Immunother 62: 897-908 
102. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD. 
2012. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing 
tumors after depletion of effector/memory-like regulatory T cells. PLoS One 7: e31962 
103. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler 
JG, Emens LA, Reilly RT, Jaffee EM. 2005. Recruitment of latent pools of high-avidity 
CD8(+) T cells to the antitumor immune response. J Exp Med 201: 1591-602 
104. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. 1999. Tumor 
rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal 
antibody. Cancer Res 59: 3128-33 
105. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. 
2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by 
regulatory T cells. J Exp Med 200: 771-82 
106. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. 2007. Vaccination against the 
forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67: 
371-80 
107. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. 2008. Comparative methodologies 
of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 333: 
167-79 
108. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, 
Allison JP, Toes RE, Offringa R, Melief CJ. 2001. Synergism of cytotoxic T lymphocyte-
associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor 
therapy reveals alternative pathways for suppression of autoreactive cytotoxic T 
lymphocyte responses. J Exp Med 194: 823-32 
109. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu 
S, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR. 2006. Glucocorticoid-
induced TNF receptor family related gene activation overcomes tolerance/ignorance to 
melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176: 
6434-42 
110. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, 
Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ. 2010. Dendritic cell 
vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II 
study in metastatic melanoma patients. Clin Cancer Res 16: 5067-78 
111. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ, Jr., Colligon TA, Trosko JA, 
Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, 
Vonderheide RH. 2012. CD25 blockade depletes and selectively reprograms regulatory T 
cells in concert with immunotherapy in cancer patients. Sci Transl Med 4: 134ra62 
112. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, 
Gilboa E, Vieweg J. 2005. Enhancement of vaccine-mediated antitumor immunity in 
cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-33 
113. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. 2005. Inability of a 
fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to 
eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28: 582-92 
114. Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan 
J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. 2011. Phase II trial of the 
regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage 
IV melanoma. BMC Cancer 11: 515 
 
 
83 
 
115. Powell DJ, Jr., Attia P, Ghetie V, Schindler J, Vitetta ES, Rosenberg SA. 2008. Partial 
reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant 
immunotoxin administration. J Immunother 31: 189-98 
116. Powell DJ, Jr., Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, 
Mavroukakis S, Kreitman RJ, Rosenberg SA, Pastan I. 2007. Administration of a CD25-
directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective 
partial reduction in regulatory T cells in vivo. J Immunol 179: 4919-28 
117. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, 
Sakaguchi S. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 
271-5 
118. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. 2009. Blockade of 
CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor 
activity of anti-CTLA-4 antibodies. J Exp Med 206: 1717-25 
119. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, 
Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, 
Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt 
I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. 
2010. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J 
Med 363: 711-23 
120. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura 
T, Chiba T, Sakaguchi S. 2005. Treatment of advanced tumors with agonistic anti-GITR 
mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp 
Med 202: 885-91 
121. Nishikawa H, Kato T, Hirayama M, Orito Y, Sato E, Harada N, Gnjatic S, Old LJ, Shiku H. 
2008. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor 
necrosis factor receptor signaling. Cancer Res 68: 5948-54 
122. Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, 
Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu 
HM, Urba WJ, Weinberg AD, Curti B, Fox BA. 2010. Signaling through OX40 enhances 
antitumor immunity. Semin Oncol 37: 524-32 
123. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. 2005. 
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a 
novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-51 
124. Piconese S, Valzasina B, Colombo MP. 2008. OX40 triggering blocks suppression by 
regulatory T cells and facilitates tumor rejection. J Exp Med 205: 825-39 
125. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. 2000. Therapeutic 
efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site 
of tumor growth. Cancer Res 60: 5514-21 
126. Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, 
Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD. 2012. 
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory 
and terminally differentiated phenotype. J Exp Med 209: 2113-26 
127. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ. 2011. 
CD73-deficient mice have increased antitumor immunity and are resistant to 
experimental metastasis. Cancer Res 71: 2892-900 
128. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, 
Smyth MJ. 2010. Anti-CD73 antibody therapy inhibits breast tumor growth and 
metastasis. Proc Natl Acad Sci U S A 107: 1547-52 
 
 
 
 
84 
 
129. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. 2011. CD73 has 
distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in 
mice. J Clin Invest 121: 2371-82 
130. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. 2010. 
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-
induced immune suppression. Cancer Res 70: 2245-55 
131. Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, Smyth MJ. 2012. CD73-
deficient mice are resistant to carcinogenesis. Cancer Res 72: 2190-6 
132. Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators of the 
immune system. Nat Rev Immunol 9: 162-74 
133. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. 
2009. Increased circulating myeloid-derived suppressor cells correlate with clinical 
cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide 
chemotherapy. Cancer Immunol Immunother 58: 49-59 
134. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso 
G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S. 
2011. A human promyelocytic-like population is responsible for the immune suppression 
mediated by myeloid-derived suppressor cells. Blood 118: 2254-65 
135. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, 
Rossi CR, Nitti D, Bronte V, Zanovello P. 2009. IL4Ralpha+ myeloid-derived suppressor 
cell expansion in cancer patients. J Immunol 182: 6562-8 
136. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB. 2010. 
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 70: 
443-55 
137. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, 
Korangy F. 2008. A new population of myeloid-derived suppressor cells in hepatocellular 
carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135: 234-
43 
138. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani 
G, Rivoltini L. 2007. Identification of a new subset of myeloid suppressor cells in 
peripheral blood of melanoma patients with modulation by a granulocyte-macrophage 
colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25: 2546-53 
139. Sica A, Bronte V. 2007. Altered macrophage differentiation and immune dysfunction in 
tumor development. J Clin Invest 117: 1155-66 
140. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, 
Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V. 2006. Tumors induce a 
subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J 
Clin Invest 116: 2777-90 
141. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, Liu Y, Li D, Yuan Y, Zhang GM, Feng 
ZH. 2007. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to 
cancers. Cancer Lett 252: 86-92 
142. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, 
Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarato L, 
Fruttero R, Gasco A, Bronte V, Viola A. 2011. Chemokine nitration prevents intratumoral 
infiltration of antigen-specific T cells. J Exp Med 208: 1949-62 
143. Greifenberg V, Ribechini E, Rossner S, Lutz MB. 2009. Myeloid-derived suppressor cell 
activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J 
Immunol 39: 2865-76 
144. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. 
2009. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus 
"N2" TAN. Cancer Cell 16: 183-94 
 
 
85 
 
145. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. 2007. Prostaglandin E2 
promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 
67: 4507-13 
146. Zhang HG, Grizzle WE. 2011. Exosomes and cancer: a newly described pathway of 
immune suppression. Clin Cancer Res 17: 959-64 
147. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. 2009. Myeloid-
derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T 
cells. J Immunol 183: 937-44 
148. Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M, 
Nishi N, Yamauchi A, Quintana FJ, Sobel RA, Hirashima M, Kuchroo VK. 2010. Tim-
3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ 
myeloid cells. J Immunol 185: 1383-92 
149. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, 
Lehner F, Manns MP, Greten TF, Korangy F. 2009. Myeloid derived suppressor cells 
inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 
receptor. Hepatology 50: 799-807 
150. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. 2011. Plasticity of 
human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 
117: 6532-41 
151. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, Dikov 
MM, Feoktistov I. 2011. Adenosinergic regulation of the expansion and 
immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 187: 6120-9 
152. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan 
PY, Chen SH. 2009. The novel role of tyrosine kinase inhibitor in the reversal of immune 
suppression and modulation of tumor microenvironment for immune-based cancer 
therapies. Cancer Res 69: 2514-22 
153. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. 
2010. Direct and differential suppression of myeloid-derived suppressor cell subsets by 
sunitinib is compartmentally constrained. Cancer Res 70: 3526-36 
154. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood 
L, Garcia J, Dreicer R, Bukowski R, Finke JH. 2009. Sunitinib mediates reversal of 
myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin 
Cancer Res 15: 2148-57 
155. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, 
Gabrilovich DI. 2006. All-trans-retinoic acid improves differentiation of myeloid cells and 
immune response in cancer patients. Cancer Res 66: 9299-307 
156. Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR. 2012. Paclitaxel 
promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in 
a TLR4-independent manner. J Immunotoxicol 9: 292-300 
157. Sevko A, Kremer V, Falk C, Umansky L, Shurin MR, Shurin GV, Umansky V. 2012. 
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma 
antigens in normal mice. J Immunotoxicol 9: 275-81 
158. Shurin MR, Naiditch H, Gutkin DW, Umansky V, Shurin GV. 2012. 
ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic 
agents. Curr Med Chem 19: 1792-803 
159. Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin 
MR, Umansky V. 2013. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-
derived suppressor cells and chronic inflammation in the spontaneous melanoma model. 
J Immunol 190: 2464-71 
 
 
 
86 
 
160. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. 2005. Gemcitabine selectively 
eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and 
enhances antitumor immune activity. Clin Cancer Res 11: 6713-21 
161. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, 
Rebe C, Ghiringhelli F. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-
derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. 
Cancer Res 70: 3052-61 
162. Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, Lin PC. 2011. Rgs2 mediates 
pro-angiogenic function of myeloid derived suppressor cells in the tumor 
microenvironment via upregulation of MCP-1. PLoS One 6: e18534 
163. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, 
Kitabatake M, Kakimi K, Mukaida N, Matsushima K. 2008. Chemokine-mediated rapid 
turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111: 5457-66 
164. Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, Vastolo V, Navas L, 
Garrone B, Mangano G, Biondi G, Guglielmotti A. 2012. Targeting monocyte chemotactic 
protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer 
animal models. Clin Exp Metastasis 29: 585-601 
165. Capuano G, Rigamonti N, Grioni M, Freschi M, Bellone M. 2009. Modulators of arginine 
metabolism support cancer immunosurveillance. BMC Immunol 10: 1 
166. Serafini P, Mgebroff S, Noonan K, Borrello I. 2008. Myeloid-derived suppressor cells 
promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 
68: 5439-49 
167. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, 
Borrello I. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor 
immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203: 2691-
702 
168. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, 
Schadendorf D, Baniyash M, Umansky V. 2011. Chronic inflammation promotes myeloid-
derived suppressor cell activation blocking antitumor immunity in transgenic mouse 
melanoma model. Proc Natl Acad Sci U S A 108: 17111-6 
169. Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, Bronte V. 
2009. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 9: 
470-81 
170. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci 
C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V. 2005. Nitroaspirin corrects 
immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer 
vaccination. Proc Natl Acad Sci U S A 102: 4185-90 
171. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, 
Hegmans JP. 2010. COX-2 inhibition improves immunotherapy and is associated with 
decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib 
influences MDSC function. BMC Cancer 10: 464 
172. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, 
Ohlfest JR, Okada H. 2011. COX-2 blockade suppresses gliomagenesis by inhibiting 
myeloid-derived suppressor cells. Cancer Res 71: 2664-74 
173. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. 2007. Arginase, prostaglandins, and 
myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13: 721s-6s 
174. Umansky V, Sevko A. 2012. Overcoming immunosuppression in the melanoma 
microenvironment induced by chronic inflammation. Cancer Immunol Immunother 61: 
275-82 
175. Umansky V, Sevko A. 2012. Melanoma-induced immunosuppression and its 
neutralization. Semin Cancer Biol 22: 319-26 
 
 
87 
 
176. Umansky V, Sevko A. 2013. Ret transgenic mouse model of spontaneous skin 
melanoma: focus on regulatory T cells. Pigment Cell Melanoma Res  
177. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, 
Nakashima I. 1998. Transgenic mouse model for skin malignant melanoma. Oncogene 
17: 1885-8 
178. Umansky V, Abschuetz O, Osen W, Ramacher M, Zhao F, Kato M, Schadendorf D. 
2008. Melanoma-specific memory T cells are functionally active in Ret transgenic mice 
without macroscopic tumors. Cancer Res 68: 9451-8 
179. Kimpfler S, Sevko A, Ring S, Falk C, Osen W, Frank K, Kato M, Mahnke K, Schadendorf 
D, Umansky V. 2009. Skin melanoma development in ret transgenic mice despite the 
depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 183: 6330-7 
180. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Jr., 
Schabel FM, Jr. 1984. Induction and chemotherapeutic response of two transplantable 
ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-26 
181. Morikane K, Tempero RM, Sivinski CL, Nomoto M, Van Lith ML, Muto T, Hollingsworth 
MA. 1999. Organ-specific pancreatic tumor growth properties and tumor immunity. 
Cancer Immunol Immunother 47: 287-96 
182. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin 
AV. 2013. Low-dose gemcitabine depletes regulatory T cells and improves survival in the 
orthotopic Panc02 model of pancreatic cancer. Int J Cancer 133: 98-107 
183. Cui W, Kaech SM. 2010. Generation of effector CD8+ T cells and their conversion to 
memory T cells. Immunol Rev 236: 151-66 
184. Weng NP, Araki Y, Subedi K. 2012. The molecular basis of the memory T cell response: 
differential gene expression and its epigenetic regulation. Nat Rev Immunol 12: 306-15 
185. Sevko A, Umansky V. 2013. Myeloid-derived suppressor cells interact with tumors in 
terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J 
Cancer 4: 3-11 
186. Junger WG. 2011. Immune cell regulation by autocrine purinergic signalling. Nat Rev 
Immunol 11: 201-12 
187. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel 
M. 2004. Physiological control of immune response and inflammatory tissue damage by 
hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22: 657-82 
188. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. 2008. Hypoxia-adenosinergic 
immunosuppression: tumor protection by T regulatory cells and cancerous tissue 
hypoxia. Clin Cancer Res 14: 5947-52 
189. Knapp K, Zebisch M, Pippel J, El-Tayeb A, Muller CE, Strater N. 2012. Crystal structure 
of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic 
signaling. Structure 20: 2161-73 
190. Wang TF, Ou Y, Guidotti G. 1998. The transmembrane domains of ectoapyrase (CD39) 
affect its enzymatic activity and quaternary structure. J Biol Chem 273: 24814-21 
191. Strater N. 2006. Ecto-5'-nucleotidase: Structure function relationships. Purinergic Signal 
2: 343-50 
192. Zimmermann H. 1992. 5'-Nucleotidase: molecular structure and functional aspects. 
Biochem J 285 ( Pt 2): 345-65 
193. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, 
Derangere V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, 
Apetoh L, Rebe C, Ghiringhelli F. 2012. Stat3 and Gfi-1 transcription factors control Th17 
cell immunosuppressive activity via the regulation of ectonucleotidase expression. 
Immunity 36: 362-73 
 
 
 
88 
 
194. Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, 
Waldmann H. 2011. Generation of anti-inflammatory adenosine by leukocytes is 
regulated by TGF-beta. Eur J Immunol 41: 2955-65 
195. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA, Junger WG. 
2009. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. 
FASEB J 23: 1685-93 
196. Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, Ricordi C, Westendorf 
AM, Grassi F. 2011. ATP inhibits the generation and function of regulatory T cells 
through the activation of purinergic P2X receptors. Sci Signal 4: ra12 
197. Pepper M, Jenkins MK. 2011. Origins of CD4(+) effector and central memory T cells. Nat 
Immunol 12: 467-71 
198. Zhu J, Yamane H, Paul WE. 2010. Differentiation of effector CD4 T cell populations (*). 
Annu Rev Immunol 28: 445-89 
199. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, 
Junger WG. 2006. ATP release guides neutrophil chemotaxis via P2Y2 and A3 
receptors. Science 314: 1792-5 
200. Chen Y, Yao Y, Sumi Y, Li A, To UK, Elkhal A, Inoue Y, Woehrle T, Zhang Q, Hauser C, 
Junger WG. 2010. Purinergic signaling: a fundamental mechanism in neutrophil 
activation. Sci Signal 3: ra45 
201. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger WG. 2008. Ecto-
nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil 
chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem 283: 28480-6 
202. Hyman MC, Petrovic-Djergovic D, Visovatti SH, Liao H, Yanamadala S, Bouis D, Su EJ, 
Lawrence DA, Broekman MJ, Marcus AJ, Pinsky DJ. 2009. Self-regulation of 
inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 
119: 1136-49 
203. Kukulski F, Bahrami F, Ben Yebdri F, Lecka J, Martin-Satue M, Levesque SA, Sevigny J. 
2011. NTPDase1 controls IL-8 production by human neutrophils. J Immunol 187: 644-53 
204. Hock H, Hamblen MJ, Rooke HM, Traver D, Bronson RT, Cameron S, Orkin SH. 2003. 
Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. 
Immunity 18: 109-20 
205. Stagg J. 2012. The double-edge sword effect of anti-CD73 cancer therapy. 
Oncoimmunology 1: 217-8 
 
 
  
 
 
89 
 
Acknowledgements 
First of all, I would like to cordially thank my primary supervisor and first reviewer Prof. Dr. 
Viktor Umansky for the opportunity to work on my PhD project in his group. His permanent help 
and our fruitful discussions have been absolutely essential for me.  
I am equally grateful to my second supervisor Prof. Dr. Alexandr Bazhin for his professional and 
friendly advice as well as for his support and understanding at certain complicated moments of 
my work. 
I would like to thank my second reviewer and Thesis Advisory Committee member PD Dr. Anne 
Regnier-Vigouroux for her encouragement and critical advice.  
I am very grateful to Dr. Svetlana Karakhanova for all the suggestions and ideas she gave me 
during my PhD studies.  
I also wish to express my gratitude to Prof. Dr. Jochen Utikal and PD Dr. Christoffer Gebhardt 
for their kind and effective support in organizational issues. 
I am deeply grateful to Dr. Sabine Soltek for performing the orthotopical transplantation of 
Panc02 cells and to Markus Herbst for cultivating these cells as well as for his kind help and 
support. 
I am also enormously grateful to everyone who helped me to learn certain methods and 
techniques or assisted with my experiments, for their great effort and precious time: Dr. 
Alexandra Sevko, Dr. Yuhui Yang, Dr. Fernando Flores-Guzman, Kathrin Frank, Madeleine Joel, 
Inna Schwarting, Tina Maxelon, Andreas Mathes, Anca Remes, Robert Ose and Tim Bleul.  
I thank everyone I have worked with in the groups of Prof. Umansky and Prof. Bazhin for their 
help and support, in particular: Dr. Anastasia Stemke, Dr. Larissa Teixera, Katharina von Ahn, 
Julia Link, Huanhuan Jiang, Marcel Ramacher, Sushma Nayak, Tillman Michels, Cristian 
Schöter, Julia Haderer, Willi Eickelbaum, Nancy Diaz-Valdes and José Patillas. 
Last but not least, I owe my deepest gratitude to my parents and my family for their love and 
invaluable support!  
